US20110281845A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
US20110281845A1
US20110281845A1 US13/161,166 US201113161166A US2011281845A1 US 20110281845 A1 US20110281845 A1 US 20110281845A1 US 201113161166 A US201113161166 A US 201113161166A US 2011281845 A1 US2011281845 A1 US 2011281845A1
Authority
US
United States
Prior art keywords
phenyl
methylamino
alkyl
oxo
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/161,166
Inventor
Zhuoliang Chen
Mark G. Palermo
Sushil K. Sharma
Troy Smith
Christopher S. Straub
Run-Ming D. Wang
Yaping Wang
Leigh Zawel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to US13/161,166 priority Critical patent/US20110281845A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZAWEL, LEIGH, CHEN, ZHUOLIANG, PALERMO, MARK G., SHARMA, SUSHIL K., SMITH, TROY, STRAUB, CHRISTOPHER S., WANG, RUN-MING D., WANG, YAPING
Publication of US20110281845A1 publication Critical patent/US20110281845A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Definitions

  • the present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs).
  • IAPs Apoptosis Proteins
  • the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, wherein such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the IAP/Caspase 9 or Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • Programmed cell death plays a critical role in regulating cell number and in eliminating stressed or damaged cells from normal tissues. Indeed, the network of apoptotic signaling mechanisms inherent in most cell types provides a major barrier to the development and progression of human cancer. Since most commonly used radiation and chemotherapies rely on activation of apoptotic pathways to kill cancer cells, tumor cells which are capable of evading programmed cell death often become resistant to treatment.
  • Apoptosis signaling networks are classified as either extrinsic when mediated by death receptor-ligand interactions or intrinsic when mediated by cellular stress and mitochondrial permeabilization. Both pathways ultimately converge on individual Caspases. Once activated, Caspases cleave a number of cell death-related substrates, effecting destruction of the cell.
  • Tumor cells have devised a number of strategies to circumvent apoptosis.
  • One recently reported molecular mechanism involves the over expression of members of the IAP family. IAPs sabotage apoptosis by directly interacting with and neutralizing Caspases.
  • the prototype IAPs, XIAP and cIAP have three functional domains referred to as BIR 1, 2 & 3 domains. BIR3 domain interacts directly with Caspase 9 and inhibits its ability to bind and cleave its natural substrate, Procaspase 3.
  • a proapoptotic mitochondrial protein Smac (also known as DIABLO)
  • DIABLO a proapoptotic mitochondrial protein
  • the present invention relates to therapeutic molecules that bind to the Smac binding pocket thereby promoting Caspase activation. Such therapeutic molecules are useful for the treatment of proliferative diseases, including cancer.
  • the present invention relates generally to novel compounds that mimic the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs).
  • IAPs Apoptosis Proteins
  • the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the IAP/Caspase 9 or Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • the present invention relates to compounds of the formula (I)
  • R 1 is H or C 1 -C 4 alkyl
  • R 2 is H, or C 1 -C 4 alkyl which is unsubstituted or substituted by one or more substituents selected from halogen, —OH, —SH, —OCH 3 , —SCH 3 , —CN, —SCN and nitro;
  • R 3 is H, C 1 -C 4 alkyl, —CF 3 , —C 2 F 5 , —CH 2 —Z or R 2 and R 3 together form with the nitrogen form a C 3 -C 6 heteroaliphatic ring;
  • Z is H, —OH, F, Cl, —CH 3 ; —CF 3 , —CH 2 Cl, —CH 2 F or —CH 2 OH;
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • A is —CH 2 , —CH—, N, O, or S;
  • X 1 O, S, or NR a ;
  • R 4 , R a and R b are independently, H; C 1 -C 16 straight or branched alkyl; C 1 -C 16 alkenyl; C 1 -C 16 alkynyl; or C 1 -C 16 cycloalkyl; —(CH 2 ) 0-6 -phenyl; (CH 2 ) 0-6 -het; —O—C 1 -C 16 straight or branched alkyl, —S—C 1 -C 16 straight or branched alkyl; —N—C 1 -C 16 straight or branched alkyl; —O—C 1 -C 16 alkenyl; —S—C 1 -C 16 alkenyl; —N—C 1 -C 16 alkenyl —O—C 1 -C 16 cycloalkyl; —N—C 1 -C 16 cycloalkyl; —S—C 1 -C 16 cycloalkyl; —O—(
  • U is —R 5 ; —CH(R 5 )(R 6 ); —CO—N(R 5 )(R 6 ); —CO—O(R 5 ); —CO—S(R 5 ); —CS—N(R 5 )(R 6 ); —N(R 5 )—CO—N(R 5 )(R 6 ); —C 1 -C 5 -alkyl-N(R 5 )(R 6 ); —C 1 -C 5 -alkyl-O(R 6 ) or —C 1 -C 5 -alkyl-S(O) n (R 6 ) where n is 0, 1 or 2;
  • R 5 is H; C 1 -C 10 -alkyl; C 3 -C 7 -cycloalkyl; —(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —C 1 -C 10 alkyl-aryl; —(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-6 —C 3 -C 7 cycloalkyl-(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-4 CH—((CH 2 ) 1-4 -phenyl) 2 ; —(CH 2 ) 0-6 —CH(phenyl) 2 ; —C(O)—C 1 -C 10 alkyl; —C(O)—(CH 2 ) 1-6 —C 3 -C 7 cycloalkyl; —C(O)—(CH 2 ) 0-6 -phenyl; —(CH 2 ) 1-6 -he
  • R 7 and R 8 are independently H, halogen; C 1-7 alkyl; —OC 1-7 alkyl; C 1-7 cycloalkyl; or —OC 1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
  • V is R 9 ; R 10 ; CR 9 R 10 ; —C(O)—; C(hal) 2 ; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O) 2 ;
  • R 9 and R 10 are independently H, halogen, C 1-7 alkyl; —OC 1-7 alkyl; C 1-7 cycloalkyl; or —OC 1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
  • R 6 is H; —C 1 -C 10 alkyl; —OH; —O—C 1 -C 10 -alkyl; —(CH 2 ) 0-6 —C 3 -C 7 -cycloalkyl; —O—(CH 2 ) 0-6 -aryl; —(CH 2 ) 0-6 -aryl; phenyl; —(CH 2 ) 1-6 -het; —O—(CH 2 ) 1-6 -het; —N(R 12 )(R 13 ); —CNOR 12 ; —S—R 12 ; —S(O)—R 12 ; —S(O) 2 —R 12 ; or —S(O) 2 —NR 12 R 13 wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted;
  • R 12 and R 13 are independently H; C 1 -C 10 alkyl; —(CH 2 ) 0-6 —C 3 -C 7 -cycloalkyl; —(CH 2 ) 0-6 —(CH) 0-1 (aryl) 1-2 ; —C(O)—C 1 -C 10 alkyl; —C(O)—(CH 2 ) 1-6 —C 3 -C 7 -cycloalkyl; —C(O)—O—(CH 2 ) 0-6 -aryl; —C(O)—(CH 2 ) 0-6 —O-fluorenyl; —C(O)—NH—(CH 2 ) 0-6 -aryl; —C(O)—(CH 2 ) 0-6 -aryl; or —C(O)—(CH 2 ) 1-6 -het,
  • alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted; or a substituent that facilitates transport of the molecule across a cell membrane, or R 12 and R 13 together with the nitrogen form an aromatic or aliphatic heterocycle;
  • R 11 and R 14 are C 1-7 alkyl; —(CH 2 ) 0-6 -phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • alkyl substituents may be substituted by one or more substituents selected from a double bond, halogen (hal), OH, SH, —O—C 1 -C 6 alkyl especially —OCH 3 , —S—C 1 -C 6 alkyl especially —SCH 3 , —CN, —SCN, nitro, —N(R 1 )(R 2 ) and —CF 3 ; alkyl as used in this application includes heteroalkyl wherein one of the carbon atoms in the alkyl chain is substituted with N, O or S;
  • cycloalkyl substituents may be substituted by one or more substituents selected from a double bond, C 1 -C 6 alkyl, halogen, OH, SH, —O—C 1 -C 6 alkyl especially —OCH 3 , —S—C 1 -C 6 alkyl especially —SCH 3 , —CN, —SCN, nitro and —CF 3 ; and
  • substituted phenyl or aryl are substituted by one or more substituents selected from halogen, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, nitro, —CN, —O—C(O)—C 1 -C 4 alkyl (substituted or unsubstituted) and —C(O)—O—C 1 -C 4 alkyl (substituted or unsubstituted); and pharmaceutically acceptable salts thereof.
  • the present invention also relates to a method of treating a proliferative disease comprising administering a compound of the formula (I) to a warm-blooded animal, especially a human, and the use of a compound of the formula (I), especially for treating a proliferative disease.
  • the present invention also relates to pharmaceutical preparations comprising a compound of the formula (I), especially for the treatment of a proliferative disease, a process for the manufacture of a compound of the formula (I), and novel starting materials and intermediates for their manufacture.
  • the present invention also relates to the use of a compound of formula (I) in the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.
  • R 3 has the stereochemistry indicated in formula (II), with the definitions of the variable substituents and preferences described herein also applying to compounds having the stereochemistry indicated in formula (II).
  • One embodiment of the present invention comprises a compound of formula (I):
  • R 1 is H or C 1 -C 4 alkyl
  • R 2 is H or C 1 -C 4 alkyl
  • R 3 is H or C 1 -C 4 alkyl
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • A is —CH 2 , —CH—, N, O, or S;
  • X 1 is O, S, or NR a ;
  • R 4 , R a and R b are independently, H; C 1 -C 16 straight or branched alkyl or —(CH 2 ) 0-6 -phenyl, wherein said phenyl may be unsubstituted or substituted, preferably with halo;
  • U is —R 5 ; —CH(R 5 )(R 6 ); or —CO—N(R 5 )(R 6 );
  • R 5 is H; C 1 -C 10 -alkyl; —(CH 2 ) 0-6 -phenyl; —C(O)—C 1 -C 10 alkyl; —C(O)—(CH 2 ) 0-6 -phenyl; —(CR 7 R 8 ) 0-2 -Aryl-V-Aryl; CHR 6 C(O)N(R 12 )(R 13 ); or C(O)—NH—CH(R 11 )(R 14 );
  • R 7 and R 5 are independently H, halogen; C 1-7 alkyl; —OC 1-7 alkyl; C 1-7 cycloalkyl; or —OC 1-7 cycloalkyl;
  • V is —C(O)—; C(hal) 2 ; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O) 2 ;
  • R 9 and R 10 are independently H, halogen, C 1-7 alkyl; —OC 1-7 alkyl; C 1-7 cycloalkyl; or —OC 1-7 cycloalkyl;
  • R 6 is H; —C 1 -C 10 alkyl; —OH; —O—C 1 -C 10 -alkyl; —(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-6 -aryl; —O—(CH 2 ) 0-6 -aryl; phenyl; —(CH 2 ) 1-6 -het; —O—(CH 2 ) 1-6 -het; —N(R 12 )(R 13 ); —CNOR 12 ; —S—R 12 ; —S(O)—R 12 ; —S(O) 2 —R 12 ; or —S(O) 2 —NR 12 R 13 ;
  • R 12 and R 13 are independently H; or C 1 -C 10 alkyl
  • R 11 and R 14 are C 1-7 alkyl; —(CH 2 ) 0-6 -phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • R 1 , R 2 and R 3 are independently H or C 1 -C 4 alkyl
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • A is —CH 2 , —CH—, N, O, or S;
  • X 1 is O, S, or NR a ;
  • R 4 , R a and R b are independently, H; C 1 -C 16 straight or branched alkyl; or —(CH 2 ) 0-6 -phenyl;
  • U is —R 5 ; C 1 -C 5 alkyl-N(R 5 )(R 6 ); or —CO—N(R 5 )(R 6 );
  • R 5 is H; —(CH 2 ) 0-6 -phenyl; C 1 -C 3 alkyl; -Aryl-V-Aryl-; or —C(O)—NH—CH(R 11 )(R 14 ) wherein aryl or phenyl may be unsubstituted or substituted, preferably with halo;
  • V is —O—
  • R 6 is H; —C 1 -C 10 alkyl; —OH; —O—C 1 -C 10 -alkyl; —O—(CH 2 ) 0-6 -phenyl; —(CH 2 ) 0-6 -phenyl; indanyl; or phenyl;
  • R 11 and R 14 are C 1-7 alkyl; —(CH 2 ) 0-6 -phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • compound of formula (I) has the following:
  • R 1 is H or alkyl.
  • R 2 is especially H, methyl or ethyl, particularly H or methyl, which methyl group is unsubstituted or substituted, particularly unsubstituted methyl.
  • R 2 as substituted methyl especially includes chloromethyl, dichloromethyl and especially trifluoromethyl.
  • R 3 is especially methyl or ethyl.
  • R 2 and R 3 together with the nitrogen form a heteroaliphatic ring, including saturated and unsaturated 3 to 6 membered nonaromatic rings, for example, aziridine, azetidine, azole, piperidine, piperazine, and the like, especially aziridine and azetidine.
  • R 4 is preferably H, Me, n-Bu, benzyl, phenyl or phenyl-substituted halo.
  • R a is preferably H, Me, n-Bu, benzyl, phenyl or phenyl-substituted halo.
  • R b is preferably H.
  • R 5 is —(CH 2 ) 0-6 —C 3 -C 7 -cycloalkyl-(CH 2 ) 0-6 -phenyl includes fused cycloalkyl-phenyl rings, such as indanyl, when there are no methylenes between the cycloalkyl and phenyl rings.
  • R 5 as —(CH 2 ) 0-4 CH—((CH 2 ) 1-4 -phenyl) 2 is especially —CH 2 CH 2 -phenyl, indanyl;
  • Aryl-V-Aryl is especially —(CH 2 )-Ph-O-Ph or -Ph-O-Ph; Ph-C(O)-Ph; Ph-NH-Ph; Ph-N(Me)-Ph; Ph-S-Ph, Ph-SO 2 -Ph; Ph-SO-Ph may be unsubstituted or substituted, preferably with halo.
  • R 6 is especially H.
  • a particularly important embodiment includes the compounds wherein R 5 is —C 1 -C 4 alkyl-phenyl, especially those wherein R 5 is —C 2 H 4 -phenyl and R 6 is H.
  • R 7 and R 8 is H. If one of R 7 and R 8 is other than H, it is especially hydroxy, —N(R 12 )(R 13 ), especially wherein R 12 is —C(O)—(CH 2 ) 1-6 —C 3 -C 7 -cycloalkyl, for example, wherein (CH 2 ) 1-6 —C 3 -C 7 -cycloalkyl is cyclohexylmethyl, —O—(CH 2 ) 0-6 -aryl, for example, wherein (CH 2 ) 0-6 -aryl is benzyl. If only one of R 7 and R 8 is other than H, it is preferred for R 8 to be the substituent other than H.
  • R 6 is H and R 5 is —C 1 -C 10 alkyl-aryl, particularly phenylmethyl, phenylethyl and phenylpropyl, indonyl especially phenylethyl and indanyl.
  • Halogen is fluorine, chlorine, bromine or iodine, especially fluorine and chlorine.
  • alkyl substituents include straight or branched chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl, and the like.
  • Cycloalkyl substituents include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • the het substituents include aromatic and non-aromatic heterocyclic rings and fused rings containing aromatic and non-aromatic heterocyclic rings.
  • Suitable het substituents include unsubstituted and substituted pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, 1,4-oxathiapane, furyl, thienyl, pyrrole, pyrazole, triazole, tetrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran
  • the het substituents are unsubstituted or substituted on a carbon atom by halogen, especially fluorine or chlorine, hydroxy, C 1 -C 4 alkyl, such as methyl and ethyl, C 1 -C 4 alkoxy, especially methoxy and ethoxy, nitro, —O—C(O)—C 1 -C 4 alkyl or —C(O)—O—C 1 -C 4 -alkyl or on a nitrogen by C 1 -C 4 alkyl, especially methyl or ethyl, —O—C(O)—C 1 -C 4 alkyl or —C(O)—O—C 1 -C 4 alkyl, such as carbomethoxy or carboethoxy.
  • halogen especially fluorine or chlorine
  • hydroxy C 1 -C 4 alkyl, such as methyl and ethyl, C 1 -C 4 alkoxy, especially methoxy and ethoxy,
  • heterocyclic ring is a nitrogen-containing ring, such as aziridine, azetidine, azole, piperidine, piperazine, morphiline, pyrrole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, and the like.
  • Such lipophilic substituents include a C 6 -C 30 alkyl which is saturated, monounsaturated, polyunsaturated, including methylene-interrupted polyene, phenyl, phenyl which substituted by one or two C 1 -C 8 alkyl groups, C 5 -C 9 cycloalkyl, C 5 -C 9 cycloalkyl which is substituted by one or two C 1 -C 8 alkyl groups, —X 1 -phenyl, —X 1 -phenyl which is substituted in the phenyl ring by one or two C 1 -C 8 alkyl groups, X 1 —C 5 -C 9 cycloalkyl or X 1 —C 5 -C 9 cycloalkyl which is substituted by one or two C 1 -C 8 alkyl groups; where X 1 is C 1 -C 24 alkyl which is saturated, monounsaturated or polyunsaturated and straight or branched
  • a compound of the invention can exist as a salt form, especially as an acid addition salt or a base addition salt.
  • a compound can exist in a salt form, such salt forms are included within the scope of the invention.
  • any salt form may be useful in chemical manipulations, such as purification procedures, only pharmaceutically acceptable salts are useful for pharmaceutically products.
  • Pharmaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts.
  • Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate.
  • metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt.
  • ammonium salts are ammonium salt and tetramethylammonium salt.
  • organic amine addition salts are salts with morpholine and piperidine.
  • amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine.
  • Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
  • the compounds of the present invention are useful for treating proliferative diseases.
  • the present invention further relates to a method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of the invention to a mammal, preferably a human, in need of such treatment.
  • a proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases).
  • the inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular,
  • a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
  • the inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
  • the present invention further relates to a method of promoting apoptosis in rapidly proliferating cells, which comprises contacting the rapidly proliferating cells with an effective apoptosis promoting amount of a non-naturally-occurring compound that binds to the Smac binding site of XIAP and/or cIAP proteins.
  • the non-naturally-occurring compound a compound of present formula (I) or (II).
  • the invention relates also to pharmaceutical compositions comprising a compound of formula (I), to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to pharmaceutical preparations and their manufacture, especially for said uses.
  • the present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such. Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient.
  • pharmacologically acceptable compounds of the present invention may be present in or employed, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers (carrier materials).
  • compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • the invention relates also to a method of treatment for a disease that responds to inhibition of a protein kinase and/or a proliferative disease, which comprises administering a (against the mentioned diseases) prophylactically or especially therapeutically effective amount of a compound of formula (I) according to the invention, or a tautomer thereof or a pharmaceutically acceptable salt thereof, especially to a warm-blooded animal, for example, a human, that, on account of one of the mentioned diseases, requires such treatment.
  • the dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals preferably is from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1,000 mg/person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.
  • compositions of the present invention are prepared in a manner known per se, for example, by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • reaction mixture is concentrated and purified by prep HPLC (column: waters prep C18 40 ⁇ 300 mm; mobile phase: gradient condition, started at CH 3 CN 10%/H 2 O 90% with 0.1% TFA, 10 minutes changed lineally to CH 3 CN 100% with 0.1% TFA; flow rate: 25 mL/min.) to give(1S,9S)-9-((S)-2-methylamino-butyrylamino)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (230 mg) as TFA salt/white solid. (NMR and MS data confirmed, U-3133-73).
  • Product 11B is dissolved hemi-aminal in 10 mL anhydrous methanol and 100 mg 10-camphorsulfonic acid is added. Methanolysis is complete in 1 hour. The resulting material is filtered and concentrated, then reconstituted with ethyl acetate and washed with saturated bicarb followed by drying over anhydrous sodium sulfate, filtered and concentrated.
  • Product 11F is reconstituted in dichloromethane (40 mL) and added trifluoroacetic acid (10 mL). Stirring until reaction complete by HPLC. Toluene is added and concentrated to an amber oil. The product is dissolved in dichloromethane and washed with saturated bicarb followed by drying over anhydrous magnesium sulfate, filtering and concentrating to an amber solid.
  • Boc-N-MeAlaOH (5.36 g, 26.4 mmol) is suspended in dichloromethane (200 mL) and EDCI (5.4 g, 28 mmol) and DMAP (3.4 g, 28 mmol) are added to obtain a clear solution.
  • 11G in dichloromethane (50 mL) is added and stirred overnight followed by quenching with saturated bicarb and extracting with dichloromethane then washing with brine, drying over anhydrous magnesium sulfate, filtering and concentrating.
  • Product 11I is reconstituted in 20% trifluoroacetatic acid in dichloromethane (50 mL). Stirring until reaction complete by HPLC. Toluene is added and concentrated to an amber oil. The product is dissolved in dichloromethane and washed with saturated bicarb followed by drying over anhydrous magnesium sulfate, filtering and concentrating. HPLC purification to yield 12. LCMS characterization ES+ 413.1 (m+1).
  • Biotinylated Smac 7-mer peptide (AVPIAQK, lysine s-amino group is biotinylated) is immobilized on streptavidin coated beads.
  • GST-BIR3 fusion protein is precipitated with FMAT beads and is detected using fluorescent tagged anti-GST antibodies.
  • non-biotinylated Smac peptide is highly effective at competing GST-BIR3 off the FMAT beads (FIG. 2).
  • the IC 50 for non-biotinylated Smac is 400 nM.
  • the IC 50 values of compounds listed in Table 1 in the described FMAT assay ranged from 0.025-10 ⁇ M.
  • the remaining GST-BIR3 fusion protein is monitored by ELISA assay involving first, incubation with goat anti-GST antibodies followed by washing and incubation with alkaline phosphatase conjugated anti-goat antibodies. Signal is amplified using Attophos (Promega) and read with Cytoflour Ex 450 nm/40 and Em 580 nm.
  • IC 50 s correspond to concentration of compound which displaces half of GST-BIR3 signal.
  • the IC 50 for non-biotinylated Smac is 400 nM.
  • the IC 50 values of compounds listed in Table 1 in the described ELISA assays ranged from 0.005-10 ⁇ M.
  • the ability of compounds to inhibit tumor cell growth in vitro was monitored using the CellTiter 96® AQ ueous Non-Radioactive Cell Proliferation Assay (Promega).
  • This assay is composed of solutions of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine methosulfate) PMS.
  • MTS is bioreduced by cells into a formazan product, the absorbance of which is measured at 490 nm.
  • the conversion of MTS into the aqueous soluble formazan product is accomplished by dehydrogenase enzymes found in metabolically active cells.
  • the quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.
  • the IC 50 values of compounds listed in Table 1 in the described cell assays ranged from 0.005-50 ⁇ M.

Abstract

The present disclosure relates to XIAP inhibitor compounds of the formula I.
Figure US20110281845A1-20111117-C00001

Description

    SUMMARY
  • The present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs). The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, wherein such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the IAP/Caspase 9 or Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • BACKGROUND
  • Programmed cell death plays a critical role in regulating cell number and in eliminating stressed or damaged cells from normal tissues. Indeed, the network of apoptotic signaling mechanisms inherent in most cell types provides a major barrier to the development and progression of human cancer. Since most commonly used radiation and chemotherapies rely on activation of apoptotic pathways to kill cancer cells, tumor cells which are capable of evading programmed cell death often become resistant to treatment.
  • Apoptosis signaling networks are classified as either extrinsic when mediated by death receptor-ligand interactions or intrinsic when mediated by cellular stress and mitochondrial permeabilization. Both pathways ultimately converge on individual Caspases. Once activated, Caspases cleave a number of cell death-related substrates, effecting destruction of the cell.
  • Tumor cells have devised a number of strategies to circumvent apoptosis. One recently reported molecular mechanism involves the over expression of members of the IAP family. IAPs sabotage apoptosis by directly interacting with and neutralizing Caspases. The prototype IAPs, XIAP and cIAP have three functional domains referred to as BIR 1, 2 & 3 domains. BIR3 domain interacts directly with Caspase 9 and inhibits its ability to bind and cleave its natural substrate, Procaspase 3.
  • It has been reported that a proapoptotic mitochondrial protein, Smac (also known as DIABLO), is capable of neutralizing XIAP and/or cIAP by binding to a peptide binding pocket (Smac binding site) on the surface of BIR3 thereby precluding interaction between XIAP and/or cIAP and Caspase 9. The present invention relates to therapeutic molecules that bind to the Smac binding pocket thereby promoting Caspase activation. Such therapeutic molecules are useful for the treatment of proliferative diseases, including cancer.
  • SUMMARY OF THE INVENTION
  • The present invention relates generally to novel compounds that mimic the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs). The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the IAP/Caspase 9 or Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • DETAILED DESCRIPTION
  • The present invention relates to compounds of the formula (I)
  • Figure US20110281845A1-20111117-C00002
  • wherein
  • R1 is H or C1-C4 alkyl;
  • R2 is H, or C1-C4 alkyl which is unsubstituted or substituted by one or more substituents selected from halogen, —OH, —SH, —OCH3, —SCH3, —CN, —SCN and nitro;
  • R3 is H, C1-C4 alkyl, —CF3, —C2F5, —CH2—Z or R2 and R3 together form with the nitrogen form a C3-C6heteroaliphatic ring;
  • Z is H, —OH, F, Cl, —CH3; —CF3, —CH2Cl, —CH2F or —CH2OH;
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • Figure US20110281845A1-20111117-C00003
    Figure US20110281845A1-20111117-C00004
    Figure US20110281845A1-20111117-C00005
  • where
  • A is —CH2, —CH—, N, O, or S;
  • X1=O, S, or NRa;
  • R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl; C1-C16 alkenyl; C1-C16 alkynyl; or C1-C16 cycloalkyl; —(CH2)0-6-phenyl; (CH2)0-6-het; —O—C1-C16 straight or branched alkyl, —S—C1-C16 straight or branched alkyl; —N—C1-C16 straight or branched alkyl; —O—C1-C16 alkenyl; —S—C1-C16 alkenyl; —N—C1-C16 alkenyl —O—C1-C16 cycloalkyl; —N—C1-C16 cycloalkyl; —S—C1-C16 cycloalkyl; —O—(CH2)0-6-phenyl; —N—(CH2)0-6-phenyl; —S—(CH2)0-6-phenyl; —O—(CH2)0-6-het; —N—(CH2)0-6-het and —S—(CH2)0-6-het wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; or R4 and Ra may form a ring;
  • U is —R5; —CH(R5)(R6); —CO—N(R5)(R6); —CO—O(R5); —CO—S(R5); —CS—N(R5)(R6); —N(R5)—CO—N(R5)(R6); —C1-C5-alkyl-N(R5)(R6); —C1-C5-alkyl-O(R6) or —C1-C5-alkyl-S(O)n(R6) where n is 0, 1 or 2;
  • R5 is H; C1-C10-alkyl; C3-C7-cycloalkyl; —(CH2)1-6—C3-C7cycloalkyl; —C1-C10alkyl-aryl; —(CH2)0-6-phenyl; —(CH2)0-6—C3-C7cycloalkyl-(CH2)0-6-phenyl; —(CH2)0-4CH—((CH2)1-4-phenyl)2; —(CH2)0-6—CH(phenyl)2; —C(O)—C1-C10alkyl; —C(O)—(CH2)1-6—C3-C7cycloalkyl; —C(O)—(CH2)0-6-phenyl; —(CH2)1-6-het; —C(O)—(CH2)1-6-het; —(CR7R8)0-2-Aryl-V-Aryl; CHR6C(O)N(R12)(R13); C(O)—NH—CH(R11)(R14) or R5 is a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;
  • or when U is —CO—N(R5)(R6); —CS—N(R5)(R6); —N(R5)—CO—N(R5)(R6); or N(R5)—CO—N(R5)(R6), R5 and R6 together with the N atom form an aromatic or aliphatic heterocycle;
  • R7 and R8 are independently H, halogen; C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
  • V is R9; R10; CR9R10; —C(O)—; C(hal)2; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O)2;
  • R9 and R10 are independently H, halogen, C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
  • R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10-alkyl; —(CH2)0-6—C3-C7-cycloalkyl; —O—(CH2)0-6-aryl; —(CH2)0-6-aryl; phenyl; —(CH2)1-6-het; —O—(CH2)1-6-het; —N(R12)(R13); —CNOR12; —S—R12; —S(O)—R12; —S(O)2—R12; or —S(O)2—NR12R13 wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted;
  • R12 and R13 are independently H; C1-C10 alkyl; —(CH2)0-6—C3-C7-cycloalkyl; —(CH2)0-6—(CH)0-1(aryl)1-2; —C(O)—C1-C10alkyl; —C(O)—(CH2)1-6—C3-C7-cycloalkyl; —C(O)—O—(CH2)0-6-aryl; —C(O)—(CH2)0-6—O-fluorenyl; —C(O)—NH—(CH2)0-6-aryl; —C(O)—(CH2)0-6-aryl; or —C(O)—(CH2)1-6-het,
  • wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted; or a substituent that facilitates transport of the molecule across a cell membrane, or R12 and R13 together with the nitrogen form an aromatic or aliphatic heterocycle;
  • where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • and wherein
  • alkyl substituents may be substituted by one or more substituents selected from a double bond, halogen (hal), OH, SH, —O—C1-C6alkyl especially —OCH3, —S—C1-C6 alkyl especially —SCH3, —CN, —SCN, nitro, —N(R1)(R2) and —CF3; alkyl as used in this application includes heteroalkyl wherein one of the carbon atoms in the alkyl chain is substituted with N, O or S;
  • cycloalkyl substituents may be substituted by one or more substituents selected from a double bond, C1-C6 alkyl, halogen, OH, SH, —O—C1-C6 alkyl especially —OCH3, —S—C1-C6 alkyl especially —SCH3, —CN, —SCN, nitro and —CF3; and
  • substituted phenyl or aryl are substituted by one or more substituents selected from halogen, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, nitro, —CN, —O—C(O)—C1-C4 alkyl (substituted or unsubstituted) and —C(O)—O—C1-C4 alkyl (substituted or unsubstituted); and pharmaceutically acceptable salts thereof.
  • The present invention also relates to a method of treating a proliferative disease comprising administering a compound of the formula (I) to a warm-blooded animal, especially a human, and the use of a compound of the formula (I), especially for treating a proliferative disease. The present invention also relates to pharmaceutical preparations comprising a compound of the formula (I), especially for the treatment of a proliferative disease, a process for the manufacture of a compound of the formula (I), and novel starting materials and intermediates for their manufacture. The present invention also relates to the use of a compound of formula (I) in the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.
  • In a particularly important embodiment of the present invention, R3 has the stereochemistry indicated in formula (II), with the definitions of the variable substituents and preferences described herein also applying to compounds having the stereochemistry indicated in formula (II).
  • Figure US20110281845A1-20111117-C00006
  • PREFERRED EMBODIMENTS
  • One embodiment of the present invention comprises a compound of formula (I):
  • Figure US20110281845A1-20111117-C00007
  • wherein
  • R1 is H or C1-C4 alkyl;
  • R2 is H or C1-C4 alkyl;
  • R3 is H or C1-C4 alkyl;
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • Figure US20110281845A1-20111117-C00008
    Figure US20110281845A1-20111117-C00009
    Figure US20110281845A1-20111117-C00010
  • where
  • A is —CH2, —CH—, N, O, or S;
  • X1 is O, S, or NRa;
  • R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl or —(CH2)0-6-phenyl, wherein said phenyl may be unsubstituted or substituted, preferably with halo;
  • U is —R5; —CH(R5)(R6); or —CO—N(R5)(R6);
  • R5 is H; C1-C10-alkyl; —(CH2)0-6-phenyl; —C(O)—C1-C10alkyl; —C(O)—(CH2)0-6-phenyl; —(CR7R8)0-2-Aryl-V-Aryl; CHR6C(O)N(R12)(R13); or C(O)—NH—CH(R11)(R14);
  • R7 and R5 are independently H, halogen; C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl;
  • V is —C(O)—; C(hal)2; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O)2;
  • R9 and R10 are independently H, halogen, C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl;
  • R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10-alkyl; —(CH2)0-6-phenyl; —(CH2)0-6-aryl; —O—(CH2)0-6-aryl; phenyl; —(CH2)1-6-het; —O—(CH2)1-6-het; —N(R12)(R13); —CNOR12; —S—R12; —S(O)—R12; —S(O)2—R12; or —S(O)2—NR12R13;
  • R12 and R13 are independently H; or C1-C10 alkyl;
  • where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • and pharmaceutically acceptable salts thereof.
  • In an especially preferred embodiment is a compound of formula (I):
  • Figure US20110281845A1-20111117-C00011
  • wherein
  • R1, R2 and R3 are independently H or C1-C4 alkyl;
  • X is a monocyclic or a bicyclic structure selected from the group consisting of:
  • Figure US20110281845A1-20111117-C00012
    Figure US20110281845A1-20111117-C00013
    Figure US20110281845A1-20111117-C00014
  • where
  • A is —CH2, —CH—, N, O, or S;
  • X1 is O, S, or NRa;
  • R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl; or —(CH2)0-6-phenyl;
  • U is —R5; C1-C5alkyl-N(R5)(R6); or —CO—N(R5)(R6);
  • R5 is H; —(CH2)0-6-phenyl; C1-C3alkyl; -Aryl-V-Aryl-; or —C(O)—NH—CH(R11)(R14) wherein aryl or phenyl may be unsubstituted or substituted, preferably with halo;
  • V is —O—;
  • R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10-alkyl; —O—(CH2)0-6-phenyl; —(CH2)0-6-phenyl; indanyl; or phenyl;
  • where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
  • aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
  • and pharmaceutically acceptable salts thereof.
  • In other preferred embodiment of the present invention compound of formula (I) has the following:
  • R1 is H or alkyl.
  • R2 is especially H, methyl or ethyl, particularly H or methyl, which methyl group is unsubstituted or substituted, particularly unsubstituted methyl. R2 as substituted methyl especially includes chloromethyl, dichloromethyl and especially trifluoromethyl.
  • R3 is especially methyl or ethyl.
  • In a particular embodiment, R2 and R3 together with the nitrogen form a heteroaliphatic ring, including saturated and unsaturated 3 to 6 membered nonaromatic rings, for example, aziridine, azetidine, azole, piperidine, piperazine, and the like, especially aziridine and azetidine.
  • R4 is preferably H, Me, n-Bu, benzyl, phenyl or phenyl-substituted halo.
  • Ra is preferably H, Me, n-Bu, benzyl, phenyl or phenyl-substituted halo.
  • Rb is preferably H.
  • R5 is —(CH2)0-6—C3-C7-cycloalkyl-(CH2)0-6-phenyl includes fused cycloalkyl-phenyl rings, such as indanyl, when there are no methylenes between the cycloalkyl and phenyl rings.
  • R5 as —(CH2)0-4CH—((CH2)1-4-phenyl)2 is especially —CH2CH2-phenyl, indanyl;
  • R5 as —(CR7, R8)0-2Aryl-V-Aryl is especially —(CH2)-Ph-O-Ph or -Ph-O-Ph; Ph-C(O)-Ph; Ph-NH-Ph; Ph-N(Me)-Ph; Ph-S-Ph, Ph-SO2-Ph; Ph-SO-Ph may be unsubstituted or substituted, preferably with halo.
  • R6 is especially H.
  • A particularly important embodiment includes the compounds wherein R5 is —C1-C4 alkyl-phenyl, especially those wherein R5 is —C2H4-phenyl and R6 is H.
  • In a particular embodiment of the present invention, one or both of R7 and R8 is H. If one of R7 and R8 is other than H, it is especially hydroxy, —N(R12)(R13), especially wherein R12 is —C(O)—(CH2)1-6—C3-C7-cycloalkyl, for example, wherein (CH2)1-6—C3-C7-cycloalkyl is cyclohexylmethyl, —O—(CH2)0-6-aryl, for example, wherein (CH2)0-6-aryl is benzyl. If only one of R7 and R8 is other than H, it is preferred for R8 to be the substituent other than H.
  • In a preferred embodiment, R6 is H and R5 is —C1-C10 alkyl-aryl, particularly phenylmethyl, phenylethyl and phenylpropyl, indonyl especially phenylethyl and indanyl.
  • The general terms used hereinbefore and hereinafter preferably have, within this disclosure, the following meanings, unless otherwise indicated:
  • Unsubstituted is intended to mean that hydrogen is the only substituent.
  • Halogen is fluorine, chlorine, bromine or iodine, especially fluorine and chlorine. Unless otherwise specified alkyl substituents include straight or branched chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl, and the like.
  • Cycloalkyl substituents include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • The het substituents include aromatic and non-aromatic heterocyclic rings and fused rings containing aromatic and non-aromatic heterocyclic rings. Suitable het substituents include unsubstituted and substituted pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, 1,4-oxathiapane, furyl, thienyl, pyrrole, pyrazole, triazole, tetrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline, and the like. The het substituents are unsubstituted or substituted on a carbon atom by halogen, especially fluorine or chlorine, hydroxy, C1-C4 alkyl, such as methyl and ethyl, C1-C4 alkoxy, especially methoxy and ethoxy, nitro, —O—C(O)—C1-C4alkyl or —C(O)—O—C1-C4-alkyl or on a nitrogen by C1-C4 alkyl, especially methyl or ethyl, —O—C(O)—C1-C4 alkyl or —C(O)—O—C1-C4 alkyl, such as carbomethoxy or carboethoxy.
  • When two substituents together with a commonly bound nitrogen are het, it is understood that the resulting heterocyclic ring is a nitrogen-containing ring, such as aziridine, azetidine, azole, piperidine, piperazine, morphiline, pyrrole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, and the like.
  • Substituents that facilitate transport of the molecule across a cell membrane are known to those of skill in the medicinal chemistry arts (see, for example, Gangewar S., Pauletti G. M., Wang B., Siahaan T. J., Stella V. J., Borchardt R. T., Drug Discovery Today, vol. 2, p 148-155 (1997) and Bundgaard H. and Moss J., Pharmaceutical Research, vol. 7, p 885 (1990)). Generally, such substituents are lipophilic substituents. Such lipophilic substituents include a C6-C30 alkyl which is saturated, monounsaturated, polyunsaturated, including methylene-interrupted polyene, phenyl, phenyl which substituted by one or two C1-C8 alkyl groups, C5-C9 cycloalkyl, C5-C9 cycloalkyl which is substituted by one or two C1-C8 alkyl groups, —X1-phenyl, —X1-phenyl which is substituted in the phenyl ring by one or two C1-C8 alkyl groups, X1—C5-C9 cycloalkyl or X1—C5-C9 cycloalkyl which is substituted by one or two C1-C8 alkyl groups; where X1 is C1-C24 alkyl which is saturated, monounsaturated or polyunsaturated and straight or branched chain.
  • It will be apparent to one of skill in the art when a compound of the invention can exist as a salt form, especially as an acid addition salt or a base addition salt. When a compound can exist in a salt form, such salt forms are included within the scope of the invention. Although any salt form may be useful in chemical manipulations, such as purification procedures, only pharmaceutically acceptable salts are useful for pharmaceutically products.
  • Pharmaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts. Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate. Examples of metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of ammonium salts are ammonium salt and tetramethylammonium salt. Examples of organic amine addition salts are salts with morpholine and piperidine. Examples of amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine. Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
  • For the purposes of isolation or purification, as well as in the case of compounds that are used further as intermediates, it is also possible to use pharmaceutically unacceptable salts, e.g., the picrates. Only pharmaceutically acceptable, non-toxic salts may be used for therapeutic purposes, however, and those salts are therefore preferred.
  • Synthetic Procedure
  • Abbreviations:
  • CH2Cl2 methylene chloride
  • CH3CN acetonitrile
  • DIBAL diisobutylaluminium hydride
  • DIPEA diisopropylethylamine
  • DME ethylene glycol dimethyl ether
  • DMF N,N-dimethylformamide
  • DTBB 4,4′-di-tert-butylbiphenyl
  • EtOAc ethyl acetate
  • HBTU O-benzyltriazol-1-yl-N,N,N,N′-tetramethyluronium hexafluorophosphate
  • HOBt 1-hydroxhbenzotriazole
  • HPLC high performance liquid chromatography
  • KOTMS potassium trimethysilanoate.
  • MeOH methanol
  • MgSO4 magnesium sulfate
  • MnO2 manganese dioxide
  • Na2CO3 sodium carbonate
  • NaHCO3 sodium bicarbonate
  • NaOH sodium hydroxide
  • Tetrakis tetrakis(triphenylphosphine)palladium(0)
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • The compounds of formula (I) may be prepared as depicted below in Scheme 1:
  • Figure US20110281845A1-20111117-C00015
    • Step A: This step involves the coupling of an amine HXU (prepared in this invention or purchased from commercial sources) with a t-Boc-L-amino acid or its derivative using standard peptide coupling agents such as DCC/HOBt or HBTU/HOBt.
    • Step B: This step involves the removal of t-Boc group with trifluoroacetic acid (TFA).
  • As discussed above, the compounds of the present invention are useful for treating proliferative diseases. Thus, the present invention further relates to a method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of the invention to a mammal, preferably a human, in need of such treatment.
  • A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular,
      • (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example, a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or
      • (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or
      • (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multi-drug resistance.
  • In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
  • The inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
  • The present invention further relates to a method of promoting apoptosis in rapidly proliferating cells, which comprises contacting the rapidly proliferating cells with an effective apoptosis promoting amount of a non-naturally-occurring compound that binds to the Smac binding site of XIAP and/or cIAP proteins. Preferably, the non-naturally-occurring compound a compound of present formula (I) or (II).
  • Pharmaceutical Compositions
  • The invention relates also to pharmaceutical compositions comprising a compound of formula (I), to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to pharmaceutical preparations and their manufacture, especially for said uses.
  • The present invention also relates to pro-drugs of a compound of formula (I) that convert in vivo to the compound of formula (I) as such. Any reference to a compound of formula (I) is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I), as appropriate and expedient.
  • The pharmacologically acceptable compounds of the present invention may be present in or employed, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as active ingredient together or in admixture with one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers (carrier materials).
  • The invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g., lymphocytes), for the treatment of (this, in a broader aspect of the invention, also includes the prevention of (=prophylaxis against)) a disease that responds to inhibition of protein kinase activity, comprising an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, preferably which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.
  • The pharmaceutical compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • The invention relates also to a method of treatment for a disease that responds to inhibition of a protein kinase and/or a proliferative disease, which comprises administering a (against the mentioned diseases) prophylactically or especially therapeutically effective amount of a compound of formula (I) according to the invention, or a tautomer thereof or a pharmaceutically acceptable salt thereof, especially to a warm-blooded animal, for example, a human, that, on account of one of the mentioned diseases, requires such treatment.
  • The dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, for example, humans of approximately 70 kg body weight, preferably is from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1,000 mg/person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.
  • The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example, by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • Examples
  • The following Examples serve to illustrate the invention without limiting the scope thereof.
  • The following examples are intended to illustrate, but not further limit, the invention.
  • Example 1 Synthesis of (1S,9S)-9-((S)-2-Methylamino-butyrylamino)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (1)
  • The title compound 1 (formula 1) is prepared according to the procedure set forth in Scheme 2.
  • Figure US20110281845A1-20111117-C00016
    Figure US20110281845A1-20111117-C00017
    Figure US20110281845A1-20111117-C00018
  • (S)-4-Benzyl-3-(4-bromo-butyryl)-oxazolidin-2-one (1A)
  • To a solution of S-(−)-4-benzyl-2-oxazolidinone (8.0 g, 45.1 mmol) in THF (75 mL) at −70° C., is added n-BuLi (19.8 mL, 49.6 mmol, 2.5 M in hexane) slowly. After stirring at −70° C. for 1 hour, 5-bromovaleryl chloride (11.7 g, 58.7 mmol) is added dropwise. After stirring at −70° C. for 20 minutes, the cooling bath is removed and the reaction mixture is warmed to 25° C. and stirred for 2 hours. The solution is diluted with 150 mL of ether, and washed with 2×100 mL of water. The combined organic layers is dried over Na2SO4 and concentrated. The crude product is purified by chromatography (hexane/EtOAc:85/15) to give a white solid (15.3 g, 99.7%). (NMR and MS data confirmed, U-3133-51-24).
  • (S)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester (1B)
  • To a solution of diisopropylamine (0.77 mL, 5.53 mmol) in THF (4 mL) at 0° C. is added BuLi (2.17 mL, 5.42 mmol, 2.5 M in hexane) dropwise. The solution is stirred at 0° C. for 30 minutes to form an LDA solution. The LDA solution is cold to −70° C. and added to a solution of (S)-4-benzyl-3-(4-bromo-butyryl)-oxazolidin-2-one (1.72 g, 5.07 mmol) in THF (4 mL) at −70° C. dropwise. After stirring at −70° C. for 2 hours, a solution of di-t-butyl azodicarboxylate (1.40 g, 6.08 mmol) in CH2Cl2 (4 mL) is added slowly. After stirring at −70° C. for 15 minutes, Bu4NI (0.28 g, 0.76 mmol) is added in one portion. After stirring at −70° C. for 10 minutes, the flask with reaction mixture is moved to a −20° C. bath and stirred overnight (16 hours). The reaction mixture is quenched to ether (50 mL) with buffer solution (50 mL, Ph=7), and the mixture is extracted with ether (3×50 mL). The organic layer is dried over Na2SO4 and concentrated. The crude product is purified by chromatography (hexane/EtOAc:70/30) to give (S)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester as white solid (1.22 g, 49.3%). (NMR and MS data confirmed, U-3133-55-30).
  • (S)-Tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester (1C)
  • To a solution of (S)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester (1.22 g, 2.5 mmol) in THF (15 mL) at 0° C., is added a solution of LiOH (7 mL, 5% in H2O). After stirring at 0° C. for 2 hours, the reaction mixture is diluted with 15 mL of water and extracted with 20 mL of ether. The ether layer is extracted with 10 mL of saturated NaHCO3. The combined aqueous layers is acidified with saturated NaHSO4 to Ph=2, and extracted with CH2Cl2 (3×20 mL). The combined organic layers is dried over Na2SO4 and concentrated to give clued product (0.83 g) as a pale gum without further purification for next step reaction. (NMR and MS data confirmed, U-3133-56-22).
  • (S)-3-Phenethylcarbamoyl-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester (1D)
  • To a solution of (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester (83 mg, 2.5 mmol) in DMF (10 mL) at room temperature, is added diisopropylethylamine (1.4 mL) slowly. After stirring at room temperature for 20 minutes, to the reaction mixture, is added phenethylamine (445 mg, 3.67 mmol), and followed by a solution of HOBT (545 mg, 4.04 mmol) and HBTU (1.53 g, 4.04 mmol) in DMF (10 mL). After stirring for 1.5 hours at room temperature, the reaction solution is diluted with ether (100 mL), and washed with water(2×50 mL). The combined organic solution is concentrated. The crude product is diluted with CH2Cl2 and dried over Na2SO4, and purified by chromatography (CH2Cl2/MeOH:97/3) to give (S)-3-phenethyl carbamoyl-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester as pale gum (920 mg, 83.6% in two steps). (NMR and MS data confirmed, U-3133-57-26).
  • (S)-Hexahydro-pyridazine-3-carboxylic acid phenethyl-amide (1E)
  • To a solution of (S)-3-phenethyl carbamoyl-tetrahydro-pyridazine-1,2-dicarboxylic acid di-tert-butyl ester (920 mg, 2.12 mmol) in CH2Cl2(2 mL) at −20° C. is added TFA (4 mL, pre-cooled to −20° C.) slowly. After stirring at 0° C. for 30 minutes, the reaction mixture is concentrated by rotavaporation under room temperature. The residue is diluted with CH2Cl2/H2O (20 mL, 8/2), and neutralized with 10% NH4OH to Ph=7. After dried and concentrated to give crude (S)-hexahydropyridazine-3-carboxylic acid phenethyl-amide (376 mg, 76.4%) as pale gum without further purification for next step reaction. (NMR and MS data confirmed, U-3133-58-18).
  • (S)-3-Phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (1F)
  • To a solution of (S)-hexahydro pyridazine-3-carboxylic acid phenethyl-amide (376 mg, 1.59 mmol) and Et3N (0.66 mL) in CH2Cl2 (10 mL) at 0° C., is added benzylchloroformate (270 mg, 1.59 mmol) dropwise. After stirring at −5° C. for 1.5 hours, the reaction mixture is diluted with CH2Cl2 (50 mL) and washed with 10 mL of water. The organic layer is dried over Na2SO4 and concentrated to give (S)-3-phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (580 mg) as pale gum without further purification for next step reaction. (NMR and MS data confirmed, U-3133-59).
  • (S)-2-[(S)-4-Benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-3-phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (1G)
  • To a solution of (S)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid 5-benzyl ester (580 mg, 1.59 mmol) in ether (25 mL) at 0° C., is added PCl5 (920 mg, 4.38 mmol) in one portion. After stirring at 25° C. for 40 minutes, ether is removed by evaporation, and the residue is dissolved in 20 mL of THF, and is added to a solution of (S)-3-phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (580 mg) and N-methylmorpholine (0.74 mL, 6.77 mmol) in THF (10 mL) at 0° C. slowly. After stirring at room temperature for 2 hours, the reaction mixture is diluted with 100 mL of ether and washed with 2×20 mL of water. The combined organic layers is dried over Na2SO4 and concentrated, and purified by chromatography (CH2Cl2/MeOH:97/3) to give (S)-2-[(S)-4-benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-3-phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (1.13 g, 99.2%) as pale solid. (NMR and MS data confirmed, U-3133-62).
  • (S)-4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-5-oxo-5-((S)-6-phenethylcarbamoyl-tetrahydro-pyridazin-1-yl)-pentanoic acid (1H)
  • A solution/suspension of (S)-2-[(S)-4-benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-3-phenethylcarbamoyl-tetrahydro-pyridazine-1-carboxylic acid benzyl ester (1.13 g) and Pd/C (350 mg, 10% on carbon) in MeOH (15 mL, with 2 drops of acetic acid) in a 1,000 mL round flask is vigorously stirred at room temperature, under hydrogen gas (at atmosphere pressure) from a balloon for 3 hours. After degassed by house vacuum for 10 minutes, the reaction mixture is filtered to remove catalyst and concentrated. The crude product is diluted with CH2Cl2/H2O (10 mL, 8/2) and neutralized with 10% NH4OH to Ph=7. After dried and concentrated, the crude product is purified by chromatography (CH2Cl2/MeOH:97/3) to give (S)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-oxo-5-((S)-6-phenethylcarbamoyl-tetrahydro-pyridazin-1-yl)-pentanoic acid (0.74 g, 95.3%) as pale solid. (NMR and MS data confirmed, U-3133-63).
  • (1S,9S)-9-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (1I)
  • To a solution of (S)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-oxo-5-((S)-6-phenethylcarbamoyl-tetrahydro-pyridazin-1-yl)-pentanoic acid (0.74 g, 1.5 mmol) and N-methylmorpholine (0.6 g, 6.0 mmol) in THF (20 mL) at 0° C., is added PCl5 (470 mg, 2.25 mmol) in one portion. After stirring at 0° C. for 3 hours, the reaction mixture is concentrated and purified by chromatography (CH2Cl2/MeOH:97/3) to yield (1S,9S)-9-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (310 mg, 43.6%) as white solid. (NMR and MS data confirmed, U-3133-65).
  • (1S,9S)-9-Amino-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (1J)
  • To a mixture/suspension of (1S,9S)-9-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (310 mg, 0.70 mmol) and hydrozinehydrate (70 mg, 1.40 mmol) in ethanol (10 mL) is stirred at 60° C. for 2 hours. After cooled to room temperature and concentrated, the reaction mixture is purified by chromatography (CH2Cl2/MeOH:97/3) to give (1S,9S)-9-amino-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (240 mg, 99%) as white solid. (NMR and MS data confirmed, U-3133-67).
  • [(S)-1-((4S,7S)-6,10-Dioxo-4-phenethylcarbamoyl-octahydro-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (1K)
  • To a solution of (S)-2-(tert-butoxycarbonyl-methyl-amino)-butyric acid (167 mg, 0.77 mmol) in DMF (5 mL) at room temperature, is added diisopropylethylamine (0.48 mL) slowly. After stirring at room temperature for 20 minutes, the solution is transferred to another flask contained (1S,9S)-9-amino-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (240 mg, 0.70 mmol), and then a solution of HOBT (125 mg, 0.92 mmol) and HBTU (350 mg, 0.92 mmol) in DMF (5 mL) is added to the reaction mixture. After stirring for 1.5 hours, the reaction solution is diluted with ether (20 mL), and washed with water (2×10 mL). The combined organic layers is concentrated. The crude product is diluted with CH2Cl2(10 mL) and dried over Na2SO4, and purified by chromatography (CH2Cl2/MeOH:97/3) to give (S)-1-((4S,7S)-6,10-dioxo-4-phenethylcarbamoyl-octahydro-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (270 mg, 71.3%) as pale solid. (NMR and MS data confirmed, U-3133-69).
  • (1S,9S)-9-((S)-2-Methylamino-butyrylamino)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (1)
  • To a solution of (S)-1-((4S,7S)-6,10-dioxo-4-phenethylcarbamoyl-octahydro-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamoyl)-propyl]-methyl-carbamic acid tert-butyl ester (270 mg, 0.50 mmol) in CH2Cl2 (1 mL) at −20° C. is added TFA (5 mL, pre-cooled to −20° C.) slowly. After stirring at 0° C. for 30 minutes, the reaction mixture is concentrated and purified by prep HPLC (column: waters prep C18 40×300 mm; mobile phase: gradient condition, started at CH3CN 10%/H2O 90% with 0.1% TFA, 10 minutes changed lineally to CH3CN 100% with 0.1% TFA; flow rate: 25 mL/min.) to give(1S,9S)-9-((S)-2-methylamino-butyrylamino)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide (230 mg) as TFA salt/white solid. (NMR and MS data confirmed, U-3133-73).
  • Example 2 Synthesis of (Z)-(2S,5S)-5-ethyl-1-[(S)-2-((S)-2-methylamino-propionylamino)-pentanoyl]pyrrolidine-2-carboxylic acid phenethyl-amide (11) and (Z)-(3S,6S,10aR)-6-((S)-2-methylamino-propionylamino)-5-oxo-1,2,3,5,6,7,10,10a-octahydro-pyrrolo[1,2-a]azocine-3-carboxylic acid phenethylamide (12)
  • The title compounds 11 and 12 (formula 1) is prepared according to the procedure set forth in Scheme 3:
  • Figure US20110281845A1-20111117-C00019
    Figure US20110281845A1-20111117-C00020
  • (S)-2-Oxo-5-phenethylcarbamoyl-pyrrolidine-1-carboxylic acid benzyl ester (11A)
  • (S)-5-Oxo-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester (14.9 g, 57 mmol) is suspended in dichloromethane (100 mL) and added DMAP (7.1 g, 58 mmol) while cooling on ice (0-5° C.). The suspension immediately clarified. EDCI (11.1 g, 58 mmol) is added resulting in precipitation which quickly clarified again. Phenethylamine (6.8 mL, 54 mmol) is added slowly via syringe. The reaction is complete in one half hour. The dichloromethane layer is washed with aqueous 10% citric acid, water and saturated bicarb, then dried over anhydrous sodium sulfate, filtered and concentrated to a white solid. LCMS characterization ES+ 367.1 (m+1).
  • (S)-5-Hydroxy-1-methyl-pyrrolidine-2-carboxylic acid phenethyl-amide (11B)
  • A THF solution of 11A pyroglutamide (3.9 g, 11 mmol) is chilled to −78° C. After 15 minutes, 1 M super-hydride solution (13 mL, 13 mmol) is slowly added. After 1 hour, it is carefully quenched with saturated bicarb and added 4 mL 30% hydrogen peroxide and concentrated to half volume and reconstituted with ethyl acetate, then washed with saturated bicarb and brine and dried over anhydrous sodium sulfate, filtered and concentrated to a clear oil. LCMS characterization ES+ 369.1 (m+1).
  • (S)-5-Methoxy-1-methyl-pyrrolidine-2-carboxylic acid phenethyl-amide (11C)
  • Product 11B is dissolved hemi-aminal in 10 mL anhydrous methanol and 100 mg 10-camphorsulfonic acid is added. Methanolysis is complete in 1 hour. The resulting material is filtered and concentrated, then reconstituted with ethyl acetate and washed with saturated bicarb followed by drying over anhydrous sodium sulfate, filtered and concentrated. LCMS characterization ES+ 383.1 (m+1).
  • (2S,5R)-5-Allyl-1-methyl-pyrrolidine-2-carboxylic acid phenethyl-amide (11D)
  • A dichloromethane (20 mL) solution of 11C methylaminal (7.7 g, 20 mmol) is chilled to −78° C. After 20 minutes, allyltrimethylsilane (6.5 mL, 40 mmol) is added. After 10 more minutes 1 M titanium(IV) chloride (24 mL, 24 mmol) is added slowly by syringe. The reaction is complete after 1 hour. The resulting material is carefully quenched (frothing) with saturated bicarb and extracted with dichlormethane, then washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The product is isolated by flash chromatography (SiO2), and it crystallizes upon standing. LCMS characterization ES+ 393.1 (m+1).
  • (2S,5R)-5-Allyl-pyrrolidine-2-carboxylic acid phenethyl-amide (11E)
  • Dissolved 11D Cbz-homoallylproline amide (4.3 g, 11 mmol) in dichloromethane (11 mL, 1 M) is chilled to 0° C. Iodotrimethylsilane (5 mL, 37 mmol) is added via syringe. After complete reaction, it is diluted with diethyl ether and washed with 1 N HCl. Then it is concentrated aqueous with methanol titration to yield HCl salt of product. LCMS characterization ES+ 259.1 (m+1).
  • (2S,5R)-5-Allyl-1-((S)-2-methylamino-pent-4-enoyl)-pyrrolidine-2-carboxylic acid phenethyl-amide (11F)
  • AllylGlyOH (10.5 g, 26.4 mmol) is suspended in dichloromethane (200 mL) and EDCI (5.1 g, 26.4 mmol) and DMAP (3.2 g, 26.4 mmol) are added to obtain a clear solution. 11E homoallylproline amide in dichloromethane (50 mL) is added and stirred overnight. The product is quenched with saturated bicarb and extracted with dichloromethane, followed by washing with brine, drying over anhydrous magnesium sulfate, filtering and concentrating. The crude is used in following deprotection. LCMS characterization ES+ 456.1 (m+1).
  • (2S,5R)-5-Allyl-1-((S)-2-amino-pent-4-enoyl)-pyrrolidine-2-carboxylic acid phenethyl-amide (11G)
  • Product 11F is reconstituted in dichloromethane (40 mL) and added trifluoroacetic acid (10 mL). Stirring until reaction complete by HPLC. Toluene is added and concentrated to an amber oil. The product is dissolved in dichloromethane and washed with saturated bicarb followed by drying over anhydrous magnesium sulfate, filtering and concentrating to an amber solid. LCMS characterization ES+ 356.1 (m+1).
  • (2S,5R)-5-Allyl-1-[(S)-2-((S)-2-dimethylamino-propionylamino)-pent-4-enoyl]-pyrrolidine-2-carboxylic acid phenethyl-amide (11H)
  • Boc-N-MeAlaOH (5.36 g, 26.4 mmol) is suspended in dichloromethane (200 mL) and EDCI (5.4 g, 28 mmol) and DMAP (3.4 g, 28 mmol) are added to obtain a clear solution. 11G in dichloromethane (50 mL) is added and stirred overnight followed by quenching with saturated bicarb and extracting with dichloromethane then washing with brine, drying over anhydrous magnesium sulfate, filtering and concentrating. LCMS characterization ES+ 541.2 (m+1).
  • (Z)-(3S,6S,10aR)-6-((S)-2-Dimethylamino-propionylamino)-5-oxo-1,2,3,5,6,7,10,10a-octahydro-pyrrolo[1,2-a]azocine-3-carboxylic acid phenethyl-amide (11I)
  • Product 11G (894 mg) is dissolved in dichloromethane (50 mL) in a sealed tube under argon. Grubbs generation 2 catalyst (160 mg) is added and heated to 50° C., venting every half hour. After 6 hours, the product is concentrated and filtered through SiO2 with 10% methanol in ethyl acetate. Concentrating and isolating product by HPLC purification. LCMS characterization ES+ 513.2 (m+1).
  • (Z)-(3S,6S,10aR)-6-((S)-2-Methylamino-propionylamino)-5-oxo-1,2,3,5,6,7,10,10a-octahydro-pyrrolo[1,2-a]azocine-3-carboxylic acid phenethyl-amide (12)
  • Product 11I is reconstituted in 20% trifluoroacetatic acid in dichloromethane (50 mL). Stirring until reaction complete by HPLC. Toluene is added and concentrated to an amber oil. The product is dissolved in dichloromethane and washed with saturated bicarb followed by drying over anhydrous magnesium sulfate, filtering and concentrating. HPLC purification to yield 12. LCMS characterization ES+ 413.1 (m+1).
  • (Z)-(2S,5S)-5-Ethyl-1-[(S)-2-((S)-2-methylamino-propionylamino)-pentanoyl]-pyrrolidine-2-carboxylic acid phenethyl-amide (11)
  • Product 12 bicyclic olefin (5 mg) is dissolved in ethyl acetate (2 mL) under N2 atmosphere and added 10% palladium on carbon (20 mg). It is purged with H2 and stirred vigorously for 1 hour followed by filtering and concentrating to obtain 11. LCMS characterization ES+ 415.1 (m+1).
  • Example 3 Synthesis of (S)-2-methylamino-N-[2-oxo-1-(phenethylcarbamoyl-methyl)-6-phenyl-1,2-dihydro-pyridin-3-yl]-propionamide (15)
  • The title compound 15 (formula 1) is prepared according to the procedure set forth in Scheme 4.
  • Figure US20110281845A1-20111117-C00021
  • [6-(2-Chloro-phenyl)-2-oxo-1-(phenethylcarbamoyl-methyl)-1,2-dihydro-pyridin-3-yl]-carbamic acid benzyl ester (15B)
  • To a suspension of NaH (60% in mineral oil, 287 mg, 7.17 mmol, 1.2 eq.) in anhydrous DMF (12 mL) is added [6-(2-chloro-phenyl)-2-oxo-1,2-dihydro-pyridin-3-yl]carbamic acid benzyl ester (15A) (Bernstein, P. R. et. al., J. Med. Chem., vol. 37, p 3313-3326 (1994)) (2.121 g, 5.98 mmol). After being stirred for 30 minutes, the orange solution is cooled to 0° C. and 2-iodo-N-phenethyl-acetamide (1.902 g, 6.58 mmol, 1.1 eq.) is added. The mixture is stirred at room temperature for 3 hours and is quenched with 1 N HCl (8 mL), extracted with ethyl acetate (3×). The organic layer is washed in sequence with 1 N HCl, saturated Na2S2O3, water and brine; is dried over anhydrous Na2SO4 and concentrated. The residue is purified via silica gel chromatography (2-10% ethyl acetate in dichloromethane) to provide compound 15B as a yellow solid (605 mg, 20%):
  • 1H NMR (400 MHz, DMSO): δ 8.52 (bs, 1H), 7.96 (m, 1H), 7.93 (d, J=8H, 1H), 7.63-7.07 (m, 14H), 6.22 (d, J=8 Hz, 1H), 5.20 (bs, 2H), 4.89-3.75 (AB q, 2H), 3.20-3.11 (m, 2H), 2.57 (t, J=8 Hz, 2H); 13C NMR (100 MHz, MSO): δ 165.7, 157.0, 153.2, 139.1, 138.8, 136.4, 133.1, 132.6, 132.1, 131.4, 129.3, 128.5, 128.4, 128.3, 127.9, 129.8, 127.7, 127.5, 126.0, 121.0, 107.1, 66.1, 47.7, 40.2, 34.8; MS (ESI) m/e 516 (M+H+), 395.
  • Methyl-{(S)-1-[2-oxo-1-(phenethylcarbamoyl-methyl)-6-phenyl-1,2-dihydro-pyridin-3-ylcarbamoyl]ethyl}-carbamic acid tert-butyl ester (15C)
  • To compound 15B (595 mg, 1.15 mmol) above in anhydrous ethanol (24 mL) is added sodium methoxide (65 mg, 1.21 mmol) and palladium on carbon (10%, 236 mg, 40%). The mixture is hydrolyzed under hydrogen (1 atm) for 4 days. The mixture is filtered and washed with methanol. The filtrate is concentrated and the resulting residue is dissolved in anhydrous DMF (2 mL) followed by treatment at 0° C. with a solution prepared below: To (S)—N-methyl-N—BOC-alanine (240 mg, 1.18 mmol, 1.05 eq.) in anhydrous acetonitrile (2 mL) is added Hunig base (390 μL, 2.24 mmol, 2 eq.) and HBTU (447 mg, 1.18 mmol, 1.05 eq.) at 0° C. and kept at temperature for 30 minutes. The whole reaction mixture is stirred at room temperature for 36 hours and 50° C. for 7 hours; and quenched with water and 1 N HCl (2 mL). The mixture is extracted with ethyl acetate (3×). The organic layer is washed with water and brine; dried over anhydrous Na2SO4. Upon concentration the residue is purified through silica gel chromatography (20-30% ethyl acetate in hexane) to provide compound 15C as a white solid (86 mg, 15%):
  • 1H NMR (400 MHz, CDCl3): δ 8.70 (bs, 1H), 8.34 (d, J=8 Hz, 1H), 7.35-7.04 (m, 10H), 6.19 (bs, 1H), 6.13 (d, J=8H), 4.35 (AB q, 2H), 4.06 (q, J=4 Hz, 1H), 3.42 (m, 2H), 2.79 (bs, 3H), 2.71 (t, J=4 Hz, 2H), 1.36 (d, J=8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 170.7, 167.0, 158.1, 155.5, 142.8, 138.6, 134.5, 129.4, 129.3, 128.7, 128.6, 128.5, 127.8, 126.5, 122.3, 108.6, 80.9, 40.8, 35.5, 29.3, 28.3, 14.1, 13.7; MS (ESI) m/e 522 (M+H+).
  • (S)-2-Methylamino-N-[2-oxo-1-(phenethylcarbamoyl-methyl)-6-phenyl-1,2-dihydro-pyridin-3-yl]-propionamide (15)
  • Compound 15C (74 mg, 0.14 mmol) from above is treated with anisole (45 μL, 0.42 mmol) and TFA (1 mL) in anhydrous dichloromethane (1 mL) for 4 hours. The mixture is concentrated and the residue is treated with dichloromethane (1 mL). The solution is added dropwise to a rapidly stirring mixture of hexane and anhydrous ether (10.5 mL). The resulting slurry is filtered, leaving a white solid that is washed with the same solvent mixture twice and dried in vacuo to afford compound 1 as a TFA salt (45 mg, 59%):
  • 1H NMR (400 MHz, DMSO): δ 10.08 (s, 1H), 8.83 (bs, 2H), 8.22 (d, J=8 Hz, 1H), 8.05 (t, J=4 Hz, 1H), 7.44-7.08 (m, 10H), 6.18 (d, J=8 Hz, 1H), 4.32 (s, 2H), 4.18 (q, J=4 Hz), 3.19 (m, 2H), 2.59 (t, J=8 Hz), 2.43 (bs, 3H), 1.39 (d, J=3 Hz, 3H); 13C NMR (100 MHz, DMSO): δ 168.5, 166.4, 157.6, 157.1, 144.1, 139.2, 134.7, 129.3, 128.7, 128.6, 128.5, 128.3, 126.6, 126.1, 124.1, 106.6, 56.7, 49.0, 35.0, 30.9, 16.0; MS (ESI) m/e 433 (M+H+), 312.
  • Example 4 Synthesis of (S)—N-[6-phenyl-2-oxo-1-(3-phenoxy-benzyl)-1,2-dihydro-pyridin-3-yl]-2-methylamino-propionamide (20)
  • The title compound 20 (formula 1) is prepared according to the procedure set forth in Scheme 5:
  • Figure US20110281845A1-20111117-C00022
  • (6-Chloro-2-oxo-1,2-dihydro-pyridin-3-yl)-carbamic acid tert-butyl ester (20A)
  • A suspension of tin powder (2 g, 17.20 mmol, 2.5 eq.), ammonium chloride (2.576 g, 48.16 mmol, 7 eq.) and 6-chloro-3-nitro-1H-pyridine-2-one (1.201 g, 6.88 mmol, Moody, C. J. et al., J. Chem. Soc. Perkin Trans I, p 955 (2001)) in anhydrous methanol (14 mL) is sonicated for 3 hours. The solvent is removed from the mixture by rotary evaporation. The residue is treated with anhydrous THF (14 mL) and Boc anhydride (3.00 g, 13.76 mmol, 2 eq.) and the mixture is heated at reflux for 18 hours. More Boc anhydride (0.90 g, 0.6 mmol) is added to the mixture and reflux continued for 14 hours. The mixture is filtered through a silica gel pad with 2% methanol in methylene chloride washing. The filtrate is concentrated and the residue is purified by silica gel chromatography (0-2% methanol in methylene chloride) to afford the title compound 20A (1.12 g, 58.9%):
  • 1H NMR (400 MHz, CDCl3): δ 7.95 (bd, J=8 Hz, 1H), 7.33 (bs, 1H), 71.45 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 158.9, 152.6, 127.8, 126.5, 122.6, 107.6, 81.2, 28.3; MS (ESI) m/e 245 (M+H+), 191, 189 (U3910-65).
  • 6-Chloro-2-oxo-1-(3-phenoxy-benzyl)-1,2-dihydro-pyridin-3-yl]-carbamic acid tert-butyl ester (20B)
  • To lithium hydride (53 mg, 6.67 mmol) in anhydrous DMF/DME (7.6/2.6 mL) is added at 0° C. pyridone 20A (1.255 g, 5.13 mmol). The mixture is stirred at room temperature for 30 minutes, then 3-phenoxy-benzyl iodide (1.43 mL, 7.19 mmol) is added and the mixture is heated at 75° C. for 3 hours. The reaction mixture is quenched with icy water and extracted with ethyl acetate (3×). The organic phase is washed with brine (5×), dried over anhydrous sodium sulfate. Upon filtration and concentration the residue showed the presence of ca. 80/20 of the N-/O-alkylation products by 1H NMR (the two structures were distinguished by HMBC). The crude product is purified by silica gel chromatography (2.5-5.0% ethyl acetate in hexane) to afford the desired pyridone 20B (1.544 g, 70.5%):
  • 1H NMR (400 MHz, CDCl3): δ 7.88 (bs, d, J=8 Hz, 1H), 7.51 (bs, 1H), 71.28-6.81 (m, 9H), 6.28 (d, J=8 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 158.1, 157.6, 156.9, 152.7, 137.6, 130.0, 129.8, 128.6, 127.7, 123.4, 121.9, 119.2, 117.9, 117.8, 107.3, 81.0, 49.5, 28.2; MS (ESI) m/e 427 (M+H+), 371 (U3910-76).
  • {(S)-1-[6-Chloro-2-oxo-1-(3-phenoxy-benzyl)-1,2-dihydro-pyridin-3-ylcarbamoyl]-ethyl}-methyl-carbamic acid benzyl ester (20C)
  • To compound 20B (410 mg, 0.836 mmol) in anhydrous methylene chloride (0.65 mL) is added anisole (0.31 mL) and TFA (2.0 mL). The mixture is stirred for 2 hours and is added dropwise to a rapidly stirring mixture of methylene chloride and anhydrous ether (15/1 mL). The top solution is decanted and the bottom oil is dried in vacuo The greenish amine residue is dissolved in anhydrous methylene chloride (2.5 mL) with 2,4,6-trimethylpyridine (0.39 mL, 2.93 mmol).
  • In another flask is placed L-N-methyl Z-analine (536 mg, 2.26 mmol) and methylene chloride (2.5 mL). The mixture is treated at 0° C. with 1-chlorine-N,N,2-trimethylpropenylamine (0.30 mL, 2.26 mmol). The reaction mixture is stirred at 0° C. for 20 minutes and at the same temperature, is treated with the above mentioned amine solution. After being stirred at 0° C. for 2 hours and room temperature for 1 hour, the reaction mixture is concentrated. The residue is quenched with water and extracted with ethyl acetate (3×). The organic phase is washed with saturated citric acid, saturated sodium bicarbonate and brine (3×), dried over anhydrous sodium sulfate. Upon filtration, concentration and purification by silica gel chromatography (15-20% ethyl acetate in hexane) the desired compound 20C (363 mg, 75.0%) is obtained:
  • 1H NMR (400 MHz, CDCl3): δ 8.84 (bs, 1H), 8.30 (bs, 1H), 7.35-6.86 (m, 14H), 6.36 (d, J=8 Hz, 1H), 5.46 (AB, 2H), 5.29 (br, 2H), 5.19-4.98 (b, 1H), 2.92 (bs, 3H), 1.43 (d, J=8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 170.4, 158.2, 157.6, 156.8, 137.4, 136.3, 130.1, 129.8, 129.6, 128.5, 128.1, 127.7, 123.5, 122.0, 121.8, 119.1, 117.8, 107.2, 67.9, 55.8, 49.6, 30.0, 14.4; MS (ESI) m/e 546 (M+H+) (U3910-80, 83 and 100).
  • {(S)-1-[6-Phenyl-2-oxo-1-(3-phenoxy-benzyl)-1,2-dihydro-pyridin-3-ylcarbamoyl]-ethyl}-methyl-carbamic acid benzyl ester (20D)
  • To a mixture of compound 20C (37 mg, 0.068 mmol), phenyl boronic acid (12 mg, 0.10 mmol) tri-tert-butylphosphonium tetra fluoroborate (16 mg, 0.054 mmol), tris(dibenzylideneacetone) dipalladium (12 mg, 0.027 mmol) and potassium fluoride (61 mg, 1.0 mmol) is added under nitrogen atmosphere anhydrous THF (1.0 mL). The mixture is heated at reflux for 20 hours and is concentrated. The residue is purified by silica gel preparative TLC (40% ethyl acetate in hexane) to provide the title compound 20D (32 mg, 80%):
  • 1H NMR (400 MHz, CDCl3): δ 8.90 (bs, 1H), 8.32 (bs, 1H), 7.33-7.00 (m, 14H), 6.86 (m, 2H), 6.75 (dd, J=8, 8 Hz, 1H), 6.58 (m, 1H), 6.43 (bs, 1H), 6.10 (d, J=8 Hz, 1H), 5.18-4.75 (m, 5H), 2.88 (bs, 3H), 1.39 (d, J=8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 170.5, 158.0, 157.5, 156.8, 142.7, 138.7, 134.9, 129.9, 129.7, 129.2, 129.1, 128.5, 128.4, 128.1, 123.4, 122.0, 121.4, 119.1, 117.5, 117.0, 108.5, 64.8, 55.8, 49.2, 30.1, 13.8; MS (ESI) m/e 588 (M+H+) (U3910-108).
  • (S)—N-[6-Phenyl-2-oxo-1-(3-phenoxy-benzyl)-1,2-dihydro-pyridin-3-yl]-2-methylamino-propionamide (20)
  • Compound 20D (55 mg, 0.094 mmol) in ethanol (2 mL) is hydrogenated under 10% palladium on carbon (10 mg) and hydrogen (balloon pressure). The reaction is monitored by LCMS. Upon completion the mixture is filtered and the filtrate is concentrated and purified by HPLC to afford the title compound (5 mg, 12%):
  • 1H NMR (400 MHz, CDCl3): δ 8.96 (bs, 1H), 8.33 (d, J=8 Hz, 1H), 7.36-7.02 (m, 9H), 6.85 (d, J=8 Hz, 2H), 6.75 (dd, J=8, 8 Hz, 1H), 6.56 (d, J=8 Hz, 1H), 6.42 (bs, 1H), 6.17 (d, J=6, 1H), 5.12 (bs, 2H), 4.06 (bs, 1H), 2.70 (bs, 3H), 1.62 (d, J=4 Hz, 3H); MS (ESI) m/e 454 (M÷H+), (U3910-116).
  • Examples 1-30
  • The following compounds are prepared by methods analogs to those described herein utilizing analogous starting materials:
  • Example
    Compound Structure Number
    Figure US20110281845A1-20111117-C00023
    Example 1 MS ESI 444.55 (M + H)+
    Figure US20110281845A1-20111117-C00024
    Example 2 MS ESI 430.52 (M + H)+
    Figure US20110281845A1-20111117-C00025
    Example 3 MS ESI 416.54 (M + H)+
    Figure US20110281845A1-20111117-C00026
    Example 4 MS ESI 402.51 (M + H)+
    Figure US20110281845A1-20111117-C00027
    Example 5 MS ESI 430.2 (M + H)+
    Figure US20110281845A1-20111117-C00028
    Example 6 MS ESI 415.50 (M + H)+
    Figure US20110281845A1-20111117-C00029
    Example 7 MS ESI 416.54 (M + H)+
    Figure US20110281845A1-20111117-C00030
    Example 8 MS ESI 435.54 (M + H)+
    Figure US20110281845A1-20111117-C00031
    Example 9 MS ESI 387.50 (M + H)+
    Figure US20110281845A1-20111117-C00032
    Example 10 MS ESI 405.54 (M + H)+
    Figure US20110281845A1-20111117-C00033
    Example 11 MS ESI 415.55 (M + H)+
    Figure US20110281845A1-20111117-C00034
    Example 12 MS ESI 413.54 (M + H)+
    Figure US20110281845A1-20111117-C00035
    Example 13 MS ESI 386.43 (M + H)+
    Figure US20110281845A1-20111117-C00036
    Example 14 MS ESI 357.43 (M + H)+
    Figure US20110281845A1-20111117-C00037
    Example 15 MS ESI 433.53 (M + H)+
    Figure US20110281845A1-20111117-C00038
    Example 16 MS ESI 447.55 (M + H)+
    Figure US20110281845A1-20111117-C00039
    Example 17 MS ESI 413.54 (M + H)+
    Figure US20110281845A1-20111117-C00040
    Example 18 MS ESI 371.46 (M + H)+
    Figure US20110281845A1-20111117-C00041
    Example 19 MS ESI 447.55 (M + H)+
    Figure US20110281845A1-20111117-C00042
    Example 20 MS ESI 454.55 (M + H)+
    Figure US20110281845A1-20111117-C00043
    Example 21 MS ESI 392.47 (M + H)+
    Figure US20110281845A1-20111117-C00044
    Example 22 MS ESI 397.49 (M + H)+
    Figure US20110281845A1-20111117-C00045
    Example 23 MS ESI 383.47 (M + H)+
    Figure US20110281845A1-20111117-C00046
    Example 24 MS ESI 389.51 (M + H)+
    Figure US20110281845A1-20111117-C00047
    Example 25 MS ESI 375.49 (M + H)+
    Figure US20110281845A1-20111117-C00048
    Example 26 MS ESI 389.2 (M + H)+
    Figure US20110281845A1-20111117-C00049
    Example 27 MS ESI 405.51 (M + H)+
    Figure US20110281845A1-20111117-C00050
    Example 28 MS ESI 404.49 (M + H)+
    Figure US20110281845A1-20111117-C00051
    Example 29 MS ESI 452.53 (M + H)+
    Figure US20110281845A1-20111117-C00052
    Example 30 MS ESI 452.53 (M + H)+
    Figure US20110281845A1-20111117-C00053
    Example 31 MS ESI 392.47 (M + H)+
    Figure US20110281845A1-20111117-C00054
    Example 32 MS ESI 378.17 (M + H)+
  • In order to measure the ability of the inventive compounds to bind the BIR3 peptide binding pocket, a solution phase assay on the FMAT or ELISA technology platform is utilized.
  • Fmat
  • Biotinylated Smac 7-mer peptide (AVPIAQK, lysine s-amino group is biotinylated) is immobilized on streptavidin coated beads. GST-BIR3 fusion protein is precipitated with FMAT beads and is detected using fluorescent tagged anti-GST antibodies. Importantly, non-biotinylated Smac peptide is highly effective at competing GST-BIR3 off the FMAT beads (FIG. 2). The IC50 for non-biotinylated Smac is 400 nM. The IC50 values of compounds listed in Table 1 in the described FMAT assay ranged from 0.025-10 μM.
  • Elisa
  • Compounds are incubated with GST-BIR3 fusion protein and biotinylated SMAC peptide (AVPFAQK) in streptavidin-coated 96-well plates. For XIAP BIR3Smac Elisa, a GST-BIR3 fusion containing amino acids 248-358 from XIAP was used. For CIAP1 BIR3Smac Elisa, a GST-BIR3 fusion containing amino acids 259-364 from CIAP1 was used. Following a 30-minute incubation, wells are extensively washed. The remaining GST-BIR3 fusion protein is monitored by ELISA assay involving first, incubation with goat anti-GST antibodies followed by washing and incubation with alkaline phosphatase conjugated anti-goat antibodies. Signal is amplified using Attophos (Promega) and read with Cytoflour Ex 450 nm/40 and Em 580 nm. IC50s correspond to concentration of compound which displaces half of GST-BIR3 signal. The IC50 for non-biotinylated Smac is 400 nM. The IC50 values of compounds listed in Table 1 in the described ELISA assays ranged from 0.005-10 μM.
  • Cell Proliferation Assay
  • The ability of compounds to inhibit tumor cell growth in vitro was monitored using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega). This assay is composed of solutions of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine methosulfate) PMS. MTS is bioreduced by cells into a formazan product, the absorbance of which is measured at 490 nm. The conversion of MTS into the aqueous soluble formazan product is accomplished by dehydrogenase enzymes found in metabolically active cells. The quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture. The IC50 values of compounds listed in Table 1 in the described cell assays ranged from 0.005-50 μM.
  • Compound Structure Example Number
    Figure US20110281845A1-20111117-C00055
    Example 33 MS ESI 484.2 (M + H)+
    Figure US20110281845A1-20111117-C00056
    Example 34 MS ESI 498.2 (M + H)+
    Figure US20110281845A1-20111117-C00057
    Example 35 MS ESI 471.2 (M + H)+
    Figure US20110281845A1-20111117-C00058
    Example 36 MS ESI 485.2 (M + H)+
    Figure US20110281845A1-20111117-C00059
    Example 37 MS ESI 485.2 (M + H)+
    Figure US20110281845A1-20111117-C00060
    Example 38 MS ESI 499.2 (M + H)+
    Figure US20110281845A1-20111117-C00061
    Example 39 MS ESI 488.2 (M + H)+
    Figure US20110281845A1-20111117-C00062
    Example 40 MS ESI 520.0 (M + H)+
    Figure US20110281845A1-20111117-C00063
    Example 41 MS ESI 502.2 (M + H)+
    Figure US20110281845A1-20111117-C00064
    Example 42 MS ESI 534.1 (M + H)+
    Figure US20110281845A1-20111117-C00065
    Example 43 MS ESI 472.2 (M + H)+
    Figure US20110281845A1-20111117-C00066
    Example 44 MS ESI 486.2 (M + H)+
    Figure US20110281845A1-20111117-C00067
    Example 45 MS ESI 490.2 (M + H)+
    Figure US20110281845A1-20111117-C00068
    Example 46 MS ESI 502.8 (M + H)+
    Figure US20110281845A1-20111117-C00069
    Example 47 MS ESI 489.2 (M + H)+
    Figure US20110281845A1-20111117-C00070
    Example 48 MS ESI 503.2 (M + H)+
    Figure US20110281845A1-20111117-C00071
    Example 49 MS ESI 506.2 (M + H)+
    Figure US20110281845A1-20111117-C00072
    Example 50 MS ESI 538.2 (M + H)+
    Figure US20110281845A1-20111117-C00073
    Example 51 MS ESI 527.2 (M + H)+
    Figure US20110281845A1-20111117-C00074
    Example 52 MS ESI 555.3 (M + H)+
    Figure US20110281845A1-20111117-C00075
    Example 53 MS ESI 477.2 (M + H)+
    Figure US20110281845A1-20111117-C00076
    Example 54 MS ESI 458.2 (M + H)+
    Figure US20110281845A1-20111117-C00077
    Example 55 MS ESI 437.2 (M + H)+
    Figure US20110281845A1-20111117-C00078
    Example 56 MS ESI 455.2 (M + H)+
    Figure US20110281845A1-20111117-C00079
    Example 57 MS ESI 477.2 (M + H)+
    Figure US20110281845A1-20111117-C00080
    Example 58 MS ESI 491.2 (M + H)+
    Figure US20110281845A1-20111117-C00081
    Example 59 MS ESI 463.2 (M + H)+
    Figure US20110281845A1-20111117-C00082
    Example 60 MS ESI 491.3 (M + H)+
    Figure US20110281845A1-20111117-C00083
    Example 61 MS ESI 505.3 (M + H)+
    Figure US20110281845A1-20111117-C00084
    Example 62 MS ESI 505.3 (M + H)+
    Figure US20110281845A1-20111117-C00085
    Example 63 MS ESI 483.2 (M + H)+
    Figure US20110281845A1-20111117-C00086
    Example 64 MS ESI 468.2 (M + H)+
    Figure US20110281845A1-20111117-C00087
    Example 65 MS ESI 432.2 (M + H)+
    Figure US20110281845A1-20111117-C00088
    Example 66 MS ESI 436.2 (M + H)+
    Figure US20110281845A1-20111117-C00089
    Example 67 MS ESI 468.2 (M + H)+
    Figure US20110281845A1-20111117-C00090
    Example 68 MS ESI 418.2 (M + H)+
    Figure US20110281845A1-20111117-C00091
    Example 69 MS 429.2 (M + H)+
    Figure US20110281845A1-20111117-C00092
    Example 70 MS 433.2 (M + H)+
    Figure US20110281845A1-20111117-C00093
    Example 71 MS 449.2 (M + H)+
    Figure US20110281845A1-20111117-C00094
    Example 72 MS 465.2 (M + H)+
    Figure US20110281845A1-20111117-C00095
    Example 73 MS 451.2 (M + H)+
    Figure US20110281845A1-20111117-C00096
    Example 74 MS 469.2 (M + H)+
    Figure US20110281845A1-20111117-C00097
    Example 75 MS 463.2 (M + H)+
    Figure US20110281845A1-20111117-C00098
    Example 76 MS 476.2 (M + H)+
    Figure US20110281845A1-20111117-C00099
    Example 77 MS 443.3 (M + H)+
    Figure US20110281845A1-20111117-C00100
    Example 78 MS 447.2 (M + H)+
    Figure US20110281845A1-20111117-C00101
    Example 79 MS 463.2 (M + H)+
    Figure US20110281845A1-20111117-C00102
    Example 80 MS 479.2 (M + H)+
    Figure US20110281845A1-20111117-C00103
    Example 81 MS 465.2 (M + H)+
    Figure US20110281845A1-20111117-C00104
    Example 82 MS 483.2 (M + H)+
    Figure US20110281845A1-20111117-C00105
    Example 83 MS 414.3 (M + H)+
    Figure US20110281845A1-20111117-C00106
    Example 84 MS 418.3 (M + H)+
    Figure US20110281845A1-20111117-C00107
    Example 85 MS 434.2 (M + H)+
    Figure US20110281845A1-20111117-C00108
    Example 86 MS 450.2 (M + H)+
    Figure US20110281845A1-20111117-C00109
    Example 87 MS 436.3 (M + H)+
    Figure US20110281845A1-20111117-C00110
    Example 88 MS 454.2 (M + H)+
    Figure US20110281845A1-20111117-C00111
    Example 89 MS 448.3 (M + H)+
    Figure US20110281845A1-20111117-C00112
    Example 90 MS 462.3 (M + H)+
    Figure US20110281845A1-20111117-C00113
    Example 91 MS 464.3 (M + H)+
    Figure US20110281845A1-20111117-C00114
    Example 92 MS 432.3 (M + H)+
    Figure US20110281845A1-20111117-C00115
    Example 93 MS 450.3 (M + H)+
    Figure US20110281845A1-20111117-C00116
    Example 94 MS 428.3 (M + H)+
    Figure US20110281845A1-20111117-C00117
    Example 95 MS 464.3 (M + H)+
    Figure US20110281845A1-20111117-C00118
    Example 96 MS 468.3 (M + H)+
    Figure US20110281845A1-20111117-C00119
    Example 97 MS 400.3 (M + H)+
    Figure US20110281845A1-20111117-C00120
    Example 98 MS ESI 436.2 (M + H)+
    Figure US20110281845A1-20111117-C00121
    Example 99 MS 434.2 (M + H)+
    Figure US20110281845A1-20111117-C00122
    Example 100 MS 430.3 (M + H)+
    Figure US20110281845A1-20111117-C00123
    Example 101 MS 450.2 (M + H)+
    Figure US20110281845A1-20111117-C00124
    Example 102 MS 404.2 (M + H)+
    Figure US20110281845A1-20111117-C00125
    Example 103 MS 422.2 (M + H)+
    Figure US20110281845A1-20111117-C00126
    Example 104 MS 448.3 (M + H)+
    Figure US20110281845A1-20111117-C00127
    Example 105 MS 418.2 (M + H)+
    Figure US20110281845A1-20111117-C00128
    Example 106 MS 436.3 (M + H)+
    Figure US20110281845A1-20111117-C00129
    Example 107 MS 420.2 (M + H)+
    Figure US20110281845A1-20111117-C00130
    Example 108 MS 440.2 (M + H)+
    Figure US20110281845A1-20111117-C00131
    Example 109 MS 434.2 (M + H)+
    Figure US20110281845A1-20111117-C00132
    Example 110 MS 454.2 (M + H)+
    Figure US20110281845A1-20111117-C00133
    Example 111 MS 386.2 (M + H)+
    Figure US20110281845A1-20111117-C00134
    Example 112 MS 422.2 (M + H)+
    Figure US20110281845A1-20111117-C00135
    Example 113 MS 390.2 (M + H)+
    Figure US20110281845A1-20111117-C00136
    Example 114 MS 406.2 (M + H)+
    Figure US20110281845A1-20111117-C00137
    Example 115 MS 408.2 (M + H)+
    Figure US20110281845A1-20111117-C00138
    Example 116 MS 426.2 (M + H)+
    Figure US20110281845A1-20111117-C00139
    Example 117 MS 420.2 (M + H)+
    Figure US20110281845A1-20111117-C00140
    Example 118 MS 434.2 (M + H)+
    Figure US20110281845A1-20111117-C00141
    Example 119 MS 400.2 (M + H)+
    Figure US20110281845A1-20111117-C00142
    Example 120 MS 404.2 (M + H)+
    Figure US20110281845A1-20111117-C00143
    Example 121 MS 420.2 (M + H)+
    Figure US20110281845A1-20111117-C00144
    Example 122 MS 436.2 (M + H)+
    Figure US20110281845A1-20111117-C00145
    Example 123 MS 422.2 (M + H)+
    Figure US20110281845A1-20111117-C00146
    Example 124 MS 440.2 (M + H)+
    Figure US20110281845A1-20111117-C00147
    Example 125 MS 427.2 (M + H)+
    Figure US20110281845A1-20111117-C00148
    Example 126 MS ESI 430.2 (M + H)+
    Figure US20110281845A1-20111117-C00149
    Example 127 MS ESI 444.2 (M + H)+
    Figure US20110281845A1-20111117-C00150
    Example 128 MS ESI 498.3 (M + H)+
    Figure US20110281845A1-20111117-C00151
    Example 129 MS ESI 512.3 (M + H)+
    Figure US20110281845A1-20111117-C00152
    Example 130 MS ESI 485.3 (M + H)+
    Figure US20110281845A1-20111117-C00153
    Example 131 MS ESI 499.3 (M + H)+
    Figure US20110281845A1-20111117-C00154
    Example 132 MS ESI 534.3 (M + H)+
    Figure US20110281845A1-20111117-C00155
    Example 133 MS ESI 486.3 (M + H)+
    Figure US20110281845A1-20111117-C00156
    Example 134 MS ESI 414.3 (M + H)+
    Figure US20110281845A1-20111117-C00157
    Example 135 MS ESI 516.9 (M + H)+
    Figure US20110281845A1-20111117-C00158
    Example 136 MS ESI 517.3 (M + H)+
    Figure US20110281845A1-20111117-C00159
    Example 137 MS ESI 552.3 (M + H)+
    Figure US20110281845A1-20111117-C00160
    Example 138 MS ESI 491.3 (M + H)+
    Figure US20110281845A1-20111117-C00161
    Example 139 MS ESI 469.3 (M + H)+
    Figure US20110281845A1-20111117-C00162
    Example 140 MS ESI 491.3 (M + H)+
    Figure US20110281845A1-20111117-C00163
    Example 141 MS ESI 519.4 (M + H)+
    Figure US20110281845A1-20111117-C00164
    Example 142 MS ESI 497.3 (M + H)+
    Figure US20110281845A1-20111117-C00165
    Example 143 MS ESI 446.3 (M + H)+
    Figure US20110281845A1-20111117-C00166
    Example 144 MS ESI 482.3 (M + H)+

Claims (11)

1. A compound of the formula (II)
Figure US20110281845A1-20111117-C00167
wherein
R1 is H or C1-C4 alkyl;
R2 is H, or C1-C4 alkyl which is unsubstituted or substituted by one or more substituents selected from halogen, —OH, —SH, —OCH3, —SCH3, —CN, —SCN and nitro;
R3 is H, C1-C4 alkyl, —CF3, —CH2—Z or R2 and R3 together form with the nitrogen form a C3-C6 heteroaliphatic ring;
Z is H, —OH, F, Cl, —CH3; —CF3, —CH2Cl, —CH2F or —CH2OH;
X is or a bicyclic structure selected from the group consisting of
Figure US20110281845A1-20111117-C00168
Figure US20110281845A1-20111117-C00169
where
A is —CH2, —CH—, N, O, or S;
X1 is O, S, or NRa;
R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl; C1-C16 alkenyl; C1-C16 alkynyl; or C1-C16 cycloalkyl; —(CH2)0-6-phenyl; (CH2)0-6-het; —O—C1-C16 straight or branched alkyl, —S—C1-C16 straight or branched alkyl; —N—C1-C16 straight or branched alkyl; —O—C1-C16 alkenyl; —S—C1-C16 alkenyl; —N—C1-C16 alkenyl —O—C1-C16 cycloalkyl; —N—C1-C16 cycloalkyl; —S—C1-C16 cycloalkyl; —O—(CH2)0-6-phenyl; —N—(CH2)0-6-phenyl; —S—(CH2)0-6-phenyl; —O—(CH2)0-6-het; —N—(CH2)0-6-het or —S—(CH2)0-6-het wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; or R4 and Ra may form a ring;
U is —R5; —CH(R5)(R6); —CO—N(R5)(R6); —CO—O(R5); —CO—S(R5); —CS—N(R5)(R6); —N(R5)—CO—N(R5)(R6); —C1-C5 alkyl-N(R5)(R6); —C1-C5-alkyl-O(R6) or —C1-C5 alkyl-S(O)n(R6) where n is 0, 1 or 2;
R5 is H; C1-C10 alkyl; C3-C7 cycloalkyl; —(CH2)1-6—C3-C7 cycloalkyl; —C1-C10 alkyl-aryl; —(CH2)0-6-phenyl; —(CH2)0-6—C3-C7 cycloalkyl-(CH2)0-6-phenyl; —(CH2)0-4CH—((CH2)1-4-phenyl)2; —(CH2)0-6—CH(phenyl)2, —C(O)—C1-C10 alkyl; —C(O)—(CH2)1-6—C3-C7 cycloalkyl; —C(O)—(CH2)0-6-phenyl; —(CH2)1-6-het; —C(O)—(CH2)1-6-het; —(CR7R8)0-2-Aryl-V-Aryl; CHR6C(O)N(R12)(R13); C(O)—NH—CH(R11)(R14) or R5 is a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;
or when U is —CO—N(R5)(R6); —CS—N(R5)(R6); —N(R5)—CO—N(R5)(R6); or N(R5)—CO—N(R5)(R6), R5 and R6 together with the N atom form an aromatic or aliphatic heterocycle;
R7 and R9 are independently H, halogen; C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
V is R9; R10; CR9R10; —C(O)—; C(hal)2; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O)2;
R9 and R10 are independently H, halogen, C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl wherein the alkyl, cycloalkyl substituents may be substituted or unsubstituted;
R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10 alkyl; —(CH2)0-6—C3-C7 cycloalkyl; —O—(CH2)0-6-aryl; —(CH2)0-6-aryl; phenyl; —(CH2)1-6-het; —O—(CH2)1-6-het; —N(R12)(R13); —CNOR12; —S—R12; —S(O)—R12; —S(O)2—R12; or —S(O)2—NR12R13 wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted;
R12 and R13 are independently H; C1-C10 alkyl; —(CH2)0-6—C3-C7 cycloalkyl; —(CH2)0-6—(CH)0.1(aryl)1-2; —C(O)—C1-C10 alkyl; —C(O)—(CH2)1-6—C3-C7 cycloalkyl; —C(O)—O—(CH2)0-6-aryl; —C(O)—(CH2)0-6—O-fluorenyl; —C(O)—NH—(CH2)0-6-aryl; —C(O)—(CH2)0-6-aryl; or —C(O)—(CH2)1-6-het, wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted; or a substituent that facilitates transport of the molecule across a cell membrane, or R12 and R13 together with the nitrogen are het;
where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
or a pharmaceutically acceptable salt thereof.
2. A compound of formula (II) according to claim 1 wherein
R1 is H or C1-C4 alkyl;
R2 is H or C1-C4 alkyl;
R3 is H or C1-C4 alkyl;
X is a bicyclic structure selected from the group consisting of
Figure US20110281845A1-20111117-C00170
Figure US20110281845A1-20111117-C00171
where
A is —CH2, —CH—, N, O, or S;
X1 is O, S, or NRa;
R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl; or —(CH2)0-6-phenyl wherein phenyl is unsubstituted with halo;
U is —R5; —CH(R5)(R6); C1-C5 alkyl-N(R5)(R6); or —CO—N(R5)(R6);
R5 is H; alkyl; —(CH2)0-6-phenyl; —C(O)—C1-C10alkyl; —C(O)—(CH2)0-6-phenyl; —(CR7R8)0-2-Aryl-V-Aryl; CHR6C(O)N(R12)(R13); or C(O)—NH—CH(R11)(R14);
R7 and R8 are independently H, halogen; C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl;
V is —C(O)—; C(hal)2; —O—; —N(H)—; N(alkyl); N(aryl); S; SO; or S(O)2;
R9 and R10 are independently H, halogen, C1-7 alkyl; —OC1-7 alkyl; C1-7 cycloalkyl; or —OC1-7 cycloalkyl;
R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10 alkyl; —(CH2)0-6-phenyl; —(CH2)0-6-aryl-; —O—(CH2)0-6-aryl; phenyl; —(CH2)1-6-het; —O—(CH2)1-6-het; —N(R12)(R13); —CNOR12; —S—R12; —S(O)—R12; —S(O)2—R12; or —S(O)2—NR12R13;
R12 and R13 are independently H, or C1-C10 alkyl;
where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
or a pharmaceutically acceptable salt thereof.
3. A compound of formula (II) according to claim 1 wherein
R1, R2 and R3 are independently H or C1-C4 alkyl;
X is a bicyclic structure selected from the group consisting of
Figure US20110281845A1-20111117-C00172
Figure US20110281845A1-20111117-C00173
where
A is —CH2, —CH—, N, O, or S;
X1 is O, S, or NRa;
R4, Ra and Rb are independently, H; C1-C16 straight or branched alkyl; or —(CH2)0-6-phenyl;
U is —R5; —CO—N(R5)(R6) or C1-C5alkyl-N(R5)(R6);
R5 is H; —(CH2)0-6-phenyl; Aryl-V-Aryl; or C(O)—NH—CH(R11)(R14) wherein aryl or phenyl may be substituted or unsubstituted;
V is —O—;
R6 is H; —C1-C10 alkyl; —OH; —O—C1-C10 alkyl; —O—(CH2)0-6-phenyl; —(CH2)0-6-phenyl; indanyl or phenyl;
where R11 and R14 are C1-7 alkyl; —(CH2)0-6-phenyl; or amide;
aryl is phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
or a pharmaceutically acceptable salt thereof.
4.-5. (canceled)
6. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (II) according to claim 1.
7. A method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of formula (II) according to claim 1 to a mammal in need of such treatment.
8. A method of claim 7, wherein the mammal is a human.
9. A process to prepare compound of formula (II) according to claim 1 comprising the steps of
(a) coupling of an amine HXU with a t-Boc-L-amino acid or its derivative using a peptide coupling agent; and
(b) removing t-Boc with trifluoroacetic acid.
10. The process according to claim 9, wherein the coupling agent is DCC/HOBt or HBTU/HOBt.
11. A compound selected from the group consisting of
(1S,9S)-9-((S)-2-Methylamino-butyrylamino)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,9S)-9-((S)-2-Methylamino-propionylamino)-6,10-dioxo-octahydro-pyridazino[1,2][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,9S)-9-((S)-2-Methylamino-propionylamino)-10-oxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,8S)-8-((S)-2-Methylamino-propionylamino)-9-oxo-hexahydro-pyrazolo[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,8S)-8-((S)-2-Methylamino-butyrylamino)-5,9-dioxo-hexahydro-pyrazolo[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,8S)-8-((S)-2-Methylamino-propionylamino)-5,9-dioxo-hexahydro-pyrazolo[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(1S,8S)-8-((S)-2-Methylamino-butyrylamino)-9-oxo-hexahydro-pyrazolo[1,2-a][1,2]diazepine-1-carboxylic acid phenethyl-amide;
(3S,6S,8aS)-6-((S)-2-Methylamino-propionylamino)-5-oxo-octahydro-indolizine-3-carboxylic acid phenethyl-amide;
(3R,6S,8aS)-6-((S)-2-Methylamino-propionylamino)-5-oxo-hexahydro-thiazolo[3,2-a]pyridine-3-carboxylic acid phenethyl-amide;
(6S,10aS)-6-((S)-2-Methylamino-propionylamino)-5-oxo-decahydro-pyrrolo[1,2-a]azocine-3-carboxylic acid phenethyl-amide;
(Z)-(3S,6S,10aR)-6-((S)-2-Methylamino-propionylamino)-5-oxo-1,2,3,5,6,7,10,10a-octahydro-pyrrolo[1,2-a]azocine-3-carboxylic acid phenethyl-amide;
(S)-6-((S)-2-Methylamino-butyrylamino)-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid phenethyl-amide;
(S)-6-((S)-2-Methylamino-propionylamino)-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid phenethyl-amide;
(S)-6-((S)-2-Methylamino-propionylamino)-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid (2-cyclohexyl-ethyl)-amide;
(S)-2-Amino-N-{1-[((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-methyl]-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl}-propionamide; and
(S)-2-Amino-N-{1-[((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)methyl]-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl}-propionamide;
or a pharmaceutically acceptable salt thereof.
12. A compound selected from the group consisting of
N-[(4S,7S)-4-(Indan-2-yloxymethyl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-propionamide;
N-((4S,7S)-6,10-Dioxo-4-phenethylsulfanylmethyl-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl)-2-methylamino-propionamide;
N-[(4S,7S)-6,10-Dioxo-4-(2-phenyl-ethanesulfinylmethyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-propionamide;
N-[(4S,7S)-6,10-Dioxo-4-(2-phenyl-ethanesulfonylmethyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-propionamide;
N-[(4S,7S)-6,10-Dioxo-4-(3-phenoxy-phenyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-propionamide;
N-{(4S,7S)-4-[3-(4-Fluoro-phenoxy)-phenyl]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl}-2-methylamino-propionamide;
N-[(4S,7S)-4-(3-Benzoyl-phenyl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-propionamide;
N-[(4S,7S)-4-(3-Benzoyl-phenyl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-butyramide;
N-[(4S,7S)-4-(Indan-2-yloxymethyl)-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-butyramide;
N-((4S,7S)-6,10-Dioxo-4-phenethylsulfanylmethyl-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl)-2-methylamino-butyramide;
N-[(4S,7S)-6,10-Dioxo-4-(2-phenyl-ethanesulfinylmethyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-butyramide;
N-[(4S,7S)-6,10-Dioxo-4-(2-phenyl-ethanesulfonylmethyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-butyramide;
N-[(4S,7S)-6,10-Dioxo-4-(3-phenoxy-phenyl)-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl]-2-methylamino-butyramide;
N-{(4S,7S)-4-[3-(4-Fluoro-phenoxy)-phenyl]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl}-2-methylamino-butyramide;
N-[(3S,6S,10aS)-3-(Indan-2-yloxymethyl)-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl]-2-methylamino-propionamide;
2-Methylamino-N-((3S,6S,10aS)-5-oxo-3-phenethylsulfanylmethyl-decahydro-pyrrolo[1,2-a]azocin-6-yl)-propionamide;
2-Methylamino-N-[(3S,6S,10aS)-5-oxo-3-(2-phenyl-ethanesulfinylmethyl)-decahydro-pyrrolo[1,2-a]azocin-6-yl]-propionamide;
2-Methylamino-N-[(3S,6S,10aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-decahydro-pyrrolo[1,2-a]azocin-6-yl]-propionamide;
2-Methylamino-N-[(3S,6S,10aS)-5-oxo-3-(3-phenoxy-phenyl)-decahydro-pyrrolo[1,2-a]azocin-6-yl]-propionamide;
N-{(3S,6S,10aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl}-2-methylamino-propionamide;
N-[(3S,6S,10aS)-3-(3-Benzoyl-phenyl)-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl]-2-methylamino-propionamide;
N-[(3S,6S,10aS)-3-(3-Benzoyl-phenyl)-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl]-2-methylamino-butyramide;
2-Methylamino-N-[(3S,6S,10aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-decahydro-pyrrolo[1,2-a]azocin-6-yl]-butyramide;
2-Methylamino-N-((3S,6S,10aS)-5-oxo-3-phenethylsulfanylmethyl-decahydro-pyrrolo[1,2-a]azocin-6-yl)-butyramide
2-Methylamino-N-[(3S,6S,10aS)-5-oxo-3-(3-phenoxy-phenyl)-decahydro-pyrrolo[1,2-a]azocin-6-yl]-butyramide;
N-[(3S,6S,10aS)-3-(Indan-2-yloxymethyl)-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl]-2-methylamino-butyramide;
N-{(3S,6S,10aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-decahydro-pyrrolo[1,2-a]azocin-6-yl}-2-methylamino-butyramide;
N-[(3S,6S,9aS)-3-(Indan-2-yloxymethyl)-5-oxo-octahydro-pyrrolo[1,2-a]azepin-6-yl]-2-methylamino-propionamide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-propionamide;
N-[(3S,6S,9aS)-3-(3-Benzoyl-phenyl)-5-oxo-octahydro-pyrrolo[1,2-a]azepin-6-yl]-2-methylamino-propionamide;
2-Methylamino-N-{(3S,6S,9aS)-5-oxo-3-[3-((Z)-propenyl)-4-vinyl-cyclopent-3-enyloxymethyl]-octahydro-pyrrolo[1,2-a]azepin-6-yl}-butyramide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-butyramide;
2-Methylamino-N-((3S,6S,9aS)-5-oxo-3-phenethylsulfanylmethyl-octahydro-pyrrolo[1,2-a]azepin-6-yl)-propionamide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(3-phenoxy-phenyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-propionamide;
N-[(3S,6S,9aS)-3-(3-Benzoyl-phenyl)-5-oxo-octahydro-pyrrolo[1,2-a]azepin-6-yl]-2-methylamino-butyramide;
2-Methylamino-N-((3S,6S,9aS)-5-oxo-3-henethylsulfanylmethyl-octahydro-pyrrolo[1,2-a]azepin-6-yl)-butyramide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(3-phenoxy-phenyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-butyramide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(2-phenyl-ethanesulfinylmethyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-propionamide;
N-{(3S,6S,9aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-octahydro-pyrrolo[1,2-a]azepin-6-yl}-2-methylamino-propionamide;
2-Methylamino-N-[(3S,6S,9aS)-5-oxo-3-(2-phenyl-ethanesulfinylmethyl)-octahydro-pyrrolo[1,2-a]azepin-6-yl]-butyramide;
N-{(3S,6S,9aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-octahydro-pyrrolo[1,2-a]azepin-6-yl}-2-methylamino-butyramide;
N-[(3S,6S,8aS)-3-(Indan-2-yloxymethyl)-5-oxo-octahydro-indolizin-6-yl]-2-methylamino-propionamide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-octahydro-indolizin-6-yl]-propionamide;
2-Methylamino-N-((3S,6S,8aS)-5-oxo-3-phenethylsulfanylmethyl-octahydro-indolizin-6-yl)-propionamide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(2-phenyl-ethanesulfinylmethyl)-octahydro-indolizin-6-yl]-propionamide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(3-phenoxy-phenyl)-octahydro-indolizin-6-yl]-propionamide;
N-{(3S,6S,8aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-octahydro-indolizin-6-yl}-2-methylamino-propionamide;
N-[(3S,6S,8aS)-3-(3-Benzoyl-phenyl)-5-oxo-octahydro-indolizin-6-yl]-2-methylamino-propionamide;
N-[(3S,6S,8aS)-3-(3-Benzoyl-phenyl)-5-oxo-octahydro-indolizin-6-yl]-2-methylamino-butyramide;
N-[(3S,6S,8aS)-3-(Indan-2-yloxymethyl)-5-oxo-octahydro-indolizin-6-yl]-2-methylamino-butyramide;
2-Methylamino-N-((3S,6S,8aS)-5-oxo-3-phenethylsulfanylmethyl-octahydro-indolizin-6-yl)-butyramide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(2-phenyl-ethanesulfinylmethyl)-octahydro-indolizin-6-yl]-butyramide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(2-phenyl-ethanesulfonylmethyl)-octahydro-indolizin-6-yl]-butyramide;
2-Methylamino-N-[(3S,6S,8aS)-5-oxo-3-(3-phenoxy-phenyl)-octahydro-indolizin-6-yl]-butyramide; and
N-{(3S,6S,8aS)-3-[3-(4-Fluoro-phenoxy)-phenyl]-5-oxo-octahydro-indolizin-6-yl}-2-methylamino-butyramide;
or a pharmaceutically acceptable salt thereof.
US13/161,166 2005-06-08 2011-06-15 Organic compounds Abandoned US20110281845A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/161,166 US20110281845A1 (en) 2005-06-08 2011-06-15 Organic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68863905P 2005-06-08 2005-06-08
PCT/US2006/021850 WO2006133147A2 (en) 2005-06-08 2006-06-06 Organic compounds
US91688708A 2008-08-05 2008-08-05
US13/161,166 US20110281845A1 (en) 2005-06-08 2011-06-15 Organic compounds

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/021850 Division WO2006133147A2 (en) 2005-06-08 2006-06-06 Organic compounds
US91688708A Division 2005-06-08 2008-08-05

Publications (1)

Publication Number Publication Date
US20110281845A1 true US20110281845A1 (en) 2011-11-17

Family

ID=37052743

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/916,887 Expired - Fee Related US7989441B2 (en) 2005-06-08 2006-06-06 Organic compounds
US13/161,166 Abandoned US20110281845A1 (en) 2005-06-08 2011-06-15 Organic compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/916,887 Expired - Fee Related US7989441B2 (en) 2005-06-08 2006-06-06 Organic compounds

Country Status (11)

Country Link
US (2) US7989441B2 (en)
EP (1) EP1902065A2 (en)
JP (1) JP2008545780A (en)
KR (1) KR20080022092A (en)
CN (1) CN101193908B (en)
AU (1) AU2006255084A1 (en)
BR (1) BRPI0611922A2 (en)
CA (1) CA2610396A1 (en)
MX (1) MX2007015419A (en)
RU (1) RU2007147959A (en)
WO (1) WO2006133147A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CN103083644B (en) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Dimeric iap inhibitors
JP2008544743A (en) 2005-05-10 2008-12-11 インターミューン インコーポレイテッド Pyridone derivatives for modulating the stress-activated protein kinase system
JP4954983B2 (en) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド BIR domain binding compound
BRPI0617751A2 (en) 2005-10-25 2011-08-02 Aegera Therapeutics Inc iap bir domain binding compounds
WO2007101347A1 (en) * 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (en) 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
MX2009000824A (en) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Dimeric iap antagonists.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (en) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション IAP inhibitor
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090086582A (en) * 2006-12-07 2009-08-13 노파르티스 아게 Organic compounds
CN101535273B (en) 2006-12-07 2012-04-11 诺瓦提斯公司 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
EP2156189A1 (en) * 2007-05-07 2010-02-24 Tetralogic Pharmaceuticals Corp. Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
US8871111B2 (en) * 2008-03-18 2014-10-28 Ngk Insulators, Ltd. Piezoelectric/electrostrictive ceramic composition
WO2009149188A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2567544C2 (en) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir domain iap binding compounds
TW201249824A (en) * 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
EP2872490B1 (en) * 2012-07-13 2018-02-07 F. Hoffmann-La Roche AG Antiproliferative benzo[b]azepin-2-ones
KR20150041647A (en) 2012-08-09 2015-04-16 에프. 호프만-라 로슈 아게 Substituted hetero-azepinones
CN104470940B (en) * 2012-09-19 2018-10-16 霍夫曼-拉罗奇有限公司 The purposes of 2- oxos -2,3,4,5- tetrahydrochysene -1H- benzos [b] [Isosorbide-5-Nitrae] diaza * and its treating cancer
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
JP6382831B2 (en) * 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート Antagonists of apoptosis inhibitory protein (IAP)
EP3682873A1 (en) 2013-06-25 2020-07-22 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
CN106029650B (en) * 2013-11-18 2019-10-25 豪夫迈·罗氏有限公司 Tetrahydro-benzodiazepine * ketone
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
RU2692485C2 (en) 2014-04-02 2019-06-25 Интермьюн, Инк. Antifibrous pyridinones
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
AR101479A1 (en) 2014-08-11 2016-12-21 Boehringer Ingelheim Int DERIVATIVES OF 6-ALQUINIL-PIRIDINA
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US11053237B2 (en) 2016-05-19 2021-07-06 Boehringer Ingelheim International Gmbh Process for the manufacture of 6-alkynyl-pyridine derivatives
HUE058802T2 (en) * 2016-12-09 2022-09-28 Denali Therapeutics Inc Compounds useful as ripk1 inhibitors
CN106674228B (en) * 2016-12-09 2018-12-04 河南农业大学 Multicomponent heterocycle compound and its preparation method and application
WO2018213634A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
JPH08225586A (en) * 1995-02-22 1996-09-03 Fujisawa Pharmaceut Co Ltd New phosphoric acid derivative, its production and medicinal composition containing the same
CA2265853C (en) * 1996-09-12 2010-08-03 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
US20060019945A1 (en) 2002-02-04 2006-01-26 Chapman Kevin T Granzyme b inhibitors
DE60322120D1 (en) * 2003-02-07 2008-08-21 Genentech Inc COMPOSITIONS AND METHODS FOR REINFORCED APOPTOSIS
PE20050159A1 (en) * 2003-05-27 2005-04-19 Vertex Pharma DERIVATIVES OF 3- [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-IL) -ACETILAMINO] -4-OXO-PENTANOICO AS CASPASE INHIBITORS
BRPI0506883A (en) * 2004-01-16 2007-05-29 Univ Michigan conformational compressed smac mimetics and their uses
US7674787B2 (en) * 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
US7652703B2 (en) * 2004-07-12 2010-01-26 Micron Technology, Inc. Dual panel pixel readout in an imager
CA2573644A1 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
JP4954983B2 (en) * 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド BIR domain binding compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Davies et al, Tetrahedron Letters, (2003), 44(49), 8887-8891. *

Also Published As

Publication number Publication date
KR20080022092A (en) 2008-03-10
CA2610396A1 (en) 2006-12-14
BRPI0611922A2 (en) 2010-10-05
JP2008545780A (en) 2008-12-18
CN101193908A (en) 2008-06-04
EP1902065A2 (en) 2008-03-26
RU2007147959A (en) 2009-07-20
WO2006133147A3 (en) 2007-05-03
CN101193908B (en) 2012-04-11
US7989441B2 (en) 2011-08-02
US20090069294A1 (en) 2009-03-12
AU2006255084A1 (en) 2006-12-14
WO2006133147A2 (en) 2006-12-14
MX2007015419A (en) 2008-02-21

Similar Documents

Publication Publication Date Title
US7989441B2 (en) Organic compounds
US9783573B2 (en) IAP antagonists
US9453048B2 (en) IAP antagonists
US9603889B2 (en) IAP antagonists
CA2220055C (en) Dipeptides which promote release of growth hormone
US6432955B1 (en) Heterocyclic derivatives and their use as antithrombotic agents
US20060128632A1 (en) Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20140135270A1 (en) Macrocyclic compounds for inhibition of inhibitors of apoptosis
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
US9409888B2 (en) Dimeric compounds
US20150164974A1 (en) Iap antagonists
JP2011102312A (en) Tetrapeptide analog
AU2012300944A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
EP1323710A1 (en) Nitrogenous five-membered ring compounds
KR20080083220A (en) Inhibitors of iap
US8889712B2 (en) IAP antagonists
EP0632052B1 (en) Endothelin antagonistic peptides
US9605022B2 (en) Macrocyclic compounds for inhibition of inhibitors of apoptosis
US20200062708A1 (en) Sulfonamides as inhibitors of the uptake of extracellular citrate
AU2005229666A1 (en) Nitrogen-containing 5-membered ring compound
KR20030035589A (en) Melanocortin receptor agonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, ZHUOLIANG;PALERMO, MARK G.;SHARMA, SUSHIL K.;AND OTHERS;SIGNING DATES FROM 20060921 TO 20061002;REEL/FRAME:026592/0534

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION